| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Nautilus Biotechnology, Inc.
$0.9
-0.01 (-0.81%)
D 30Pipeline Score Diagnostics · Clinical
Market Cap
114.82 M
EPS
-0.45
P/E Ratio
-
Value Trade
743.34 K
1.15 %
Week
-46.92 %
1 Month
-64.48 %
3 Month
-68 %
6 Month
-77.89 %
5 Year
-77.89 %
All Time
Cash Data
Cash Position
-
Monthly Burn
-
Runway
-
Overview
Volume
496.16 K
52 Week Range
0.62 - 4.31
% held by Insiders
48.91 %
% held by Institutions
32.11 %
Enterprise Value
-28.55 M
Total Shares
127.26 M
Short %
3.5 %
Float Shares
41.06 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Nautilus Biotechnology, Inc.
110Total events
15Upcoming
12Tier-1 (high impact)
2021 – 2027Coverage
Upcoming catalysts 2
TBD
T2Product Launch
Subscribe to view catalyst details
TBD
T2Runway Guidance Update
Subscribe to view catalyst details
Event history 2
TBD
●Quarterly UpdateCorporate
Subscribe to view catalyst details
TBD
▲Partnership / LicenseCorporate
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
D30
Pipeline Score $13M
Pipeline ValueValuation Signal
1
Drugs Scored0.1x
rNPV / MCap Top 37%
Micro Cap (rank 588 of 931)
Percentile RankNautilus Biotechnology, Inc. faces pipeline headwinds (30/100), with $53M risk-adjusted pipeline value, led by MDMA in Post-Traumatic Stress Disorder (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MDMA Small molecule | Post-Traumatic Stress Disorder | Phase 2 | NCT05455996 | 24% | $53M | NOT YET_RECRUITING | 30 | - | - | Jun 1, 2028 | - | LOW May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in NAUT
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
NAUT Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
NAUT▼ -27.7%on this news· ran to -41% by day 3
Nautilus Biotechnology Reports Second Quarter 2026 Financial Results
Nautilus Biotechnology reported its financial results for Q2 2026, marking its first revenue from grant funding and early access program sales. The company is advancing its proteoform applications, with strong customer interest. Despite a net loss of $14.5 million, Nautilus is reallocating resources to accelerate product development and is on track for future launches.
Read more →NAUT▲ +5.3%on this news
Nautilus Biotechnology to Announce Second Quarter 2026 Financial Results on July 28, 2026
Nautilus Biotechnology, Inc. will announce its financial results for the second quarter of 2026 on July 28, 2026. The company will hold a conference call to discuss these results, along with business developments and future outlook. The webcast will be accessible via the company's website.
Read more →NAUTNautilus eBook – Proteomics and neuroscience
The latest edition of the 'Proteomics and neuroscience' eBook details how researchers utilize the Nautilus Voyager™ Platform to gain insights into tau proteoforms related to Alzheimer's disease. It includes background information on tau proteins and examples of their study at the single-molecule level. The eBook also invites readers to incorporate this platform into their research workflows.
Read more →NAUTPressing tau research questions the Nautilus Voyager™ Platform can help answer
The Nautilus Voyager™ Platform is enhancing research into tau proteins, which are crucial in Alzheimer's disease progression. Recent findings suggest that understanding tau proteoforms could lead to better diagnostic and treatment options. The platform allows researchers to explore various tau-related questions, potentially paving the way for innovative therapies. Participation in the Early Access Program is encouraged for further exploration.
Read more →NAUTExample use cases of the Nautilus Voyager™ Platform
The Nautilus Voyager™ Platform is a cutting-edge tool for proteomics, enabling researchers to analyze proteomes and proteoforms at a single-molecule level. It offers potential applications in understanding disease mechanisms, discovering biomarkers, identifying drug targets, and assessing drug toxicity. The platform's innovative design aims to enhance research capabilities in various biological fields.
Read more →NAUTFind Nautilus at an event near you – Introducing the Nautilus Events page
Nautilus is set to enhance its visibility in 2026 by attending various conferences and seminars. The company has launched an Events page to keep track of its participation and facilitate meetings. Additionally, the Iterative Mapping Early Access Program is starting, and Nautilus is eager to collaborate with organizations interested in their technology.
Read more →NAUTNautilus Biotechnology Reports First Quarter 2026 Financial Results
Nautilus Biotechnology reported its Q1 2026 financial results, highlighting the initiation of an Early Access Program for its Tau proteoform assay. The company saw a decrease in operating expenses and appointed a new VP of Global Sales to enhance customer engagement. Despite a net loss, Nautilus is making strides toward commercialization and platform validation.
Read more →NAUTStatistics and AI in proteomics research
The article discusses the importance of integrating statistics and AI into proteomics research. Parag Mallick and Olga Vitek emphasize that considering statistical analysis during experimental design can lead to more informative results. Advances in AI and machine learning are making it easier to analyze complex proteomic data, paving the way for innovative applications like artificial cells.
Read more →NAUTNautilus Biotechnology to Announce First Quarter 2026 Financial Results on April 28, 2026
Nautilus Biotechnology, Inc. will announce its financial results for Q1 2026 on April 28, 2026. The announcement will be made before market open, followed by a conference call to discuss the results and future outlook. The company focuses on advancing proteomics technology to enhance human health.
Read more →NAUTHow omics teaches us about the biology of space travel and charts a course for understanding health on earth
The article discusses how omics technologies are used to study the biological impacts of space travel on astronauts. It highlights the findings of Professor Afshin Beheshti, who has identified mitochondrial dysfunction as a key issue resulting from microgravity and radiation exposure. The research suggests that insights gained from space biology could inform health interventions on Earth, particularly for aging populations and conditions like long COVID. Additionally, advancements in omics technologies are making real-time studies in space more feasible.
Read more →NAUTNautilus in the news roundup March 2026
Nautilus Biotechnology has made significant strides in the past few months, including the launch of the Nautilus Voyager™ Platform and the Iterative Mapping Early Access Program. The company announced Baylor College of Medicine as its first customer for the program, focusing on cancer research. Additionally, Amber Faust has been appointed as Vice President of Sales to drive commercial progress. Collaborations with Weill Cornell Medicine-Qatar and the Michael J. Fox Foundation aim to advance research in Parkinson's disease.
Read more →NAUT▲ +9.1%on this newsshared move
Nautilus Biotechnology to Participate in the Investor Summit Group Virtual Conference
Nautilus Biotechnology, Inc. will participate in the Investor Summit Group Virtual Conference on March 25, 2026. The presentation will be accessible live and archived on their website. Nautilus is focused on developing a technology platform for protein analysis, aiming to advance the field of proteomics.
Read more →NAUTNautilus Lunch Seminar at US HUPO 2026 – Revealing the proteomic landscape with Iterative Mapping
At the US HUPO 2026 lunch seminar, Professor Birgit Schilling presented new insights into Alzheimer’s disease using the Nautilus Voyager Platform. The platform's Iterative Mapping technique provides detailed, reproducible quantification of tau proteoforms, revealing significant biological variations linked to Alzheimer's risk. Attendees were invited to participate in the Early Access Program to utilize this innovative technology.
Read more →NAUTNautilus Biotechnology Announces Baylor College of Medicine as First Early Access Program Customer for Voyager Platform
Nautilus Biotechnology has announced Baylor College of Medicine as the inaugural customer for its Voyager Platform through an Early Access Program. The collaboration, supported by the NIH, focuses on leveraging Nautilus' unique single-molecule proteomics method to enhance cancer research by identifying aberrant protein isoforms. This initiative aims to create a comprehensive computational toolkit for better detection of protein isoforms and biomarker analysis. The project represents a significant step towards integrating proteomic data with genomic studies in cancer biology.
Read more →NAUTIntroducing the Nautilus Voyager™ Platform!
Nautilus Biotechnology unveiled the Voyager™ Platform at US HUPO 2026, showcasing its capabilities for single-molecule proteomic analysis. The platform integrates advanced technology for accurate biological insights and disease predictions. Attendees engaged with live demonstrations, and Nautilus is inviting researchers to join an Early Access Program to utilize the platform in their studies.
Read more →NAUTRevealing the proteomic landscape at US HUPO 2026
At US HUPO 2026, Nautilus Biotechnology unveiled the Nautilus Voyager Platform, showcasing novel single-molecule data and its potential in proteomics. VP Sheri Wilcox highlighted the platform's capabilities and invited researchers to join the Early Access Program. New data revealed significant differences in tau proteoforms linked to Alzheimer's susceptibility, emphasizing the importance of proteoform-level studies.
Read more →NAUTNautilus Biotechnology Appoints Proteomics Commercial Leader Amber Faust as Vice President of Sales
Nautilus Biotechnology has appointed Amber Faust as Vice President of Sales to lead the commercialization of its Voyager™ Platform. Faust, with nearly two decades of experience in proteomics, will oversee the launch and market introduction of the platform, which aims to enhance single-molecule protein analysis. The company is progressing towards commercialization with its Iterative Mapping Early Access Program and aims for a commercial launch in late 2026.
Read more →NAUTAI and Statistics in Proteomics and Systems Biology – Interview with Professor Olga Vitek Ph.D.
In an interview, Professor Olga Vitek discusses the role of statistics and AI in proteomics and systems biology. She emphasizes the need for rigorous experimental design and the potential of computational tools to enhance biological understanding. The conversation also addresses existing gaps in utilizing these technologies effectively.
Read more →NAUT▼ -16.3%on this newsshared move
Nautilus Biotechnology Reports Fourth Quarter and Fiscal Year 2025 Financial Results
Nautilus Biotechnology reported its financial results for Q4 and fiscal year 2025, highlighting a decrease in operating expenses and a net loss reduction. The company is focused on expanding its Early Access Program and aims for commercialization by late 2026. Despite a strong cash position, it anticipates no significant revenue in 2026.
Read more →NAUT▲ +5.2%on this newsshared move
Nautilus Biotechnology Unveils Voyager Platform, Enabling Single-Molecule Iterative Mapping, at US HUPO 2026
Nautilus Biotechnology unveiled its Voyager Platform at the US HUPO 2026 conference, designed for single-molecule proteome analysis. The platform can measure up to 10 billion intact proteins simultaneously, promising to advance proteomics research. An Early Access Program is now open for researchers, with commercial launch anticipated in late 2026.
Read more →NAUT▲ +7.8%on this newsshared move
Nautilus Biotechnology to Participate in the TD Cowen 46th Annual Health Care Conference
Nautilus Biotechnology, Inc. has announced its participation in the TD Cowen 46th Annual Health Care Conference, scheduled for March 2, 2026. During the event, Nautilus management will engage in a fireside chat, which can be accessed live and archived on the company's website. Nautilus is focused on revolutionizing the field of proteomics through its innovative platform technology, aiming to enhance understanding and access to the proteome.
Read more →NAUTJoin us at at US HUPO 2026
Nautilus Biotechnology is set to participate in US HUPO 2026, starting on February 21st in St. Louis. The company will present its Iterative Mapping technology, which reveals critical insights into the proteomic landscape. Key presentations will include discussions on tau biology and the benefits of Iterative Mapping in research. Attendees can engage with the Nautilus team at Booth 25 and learn about their Early Access Program.
Read more →NAUTNautilus Biotechnology to Announce Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
Nautilus Biotechnology, Inc. announced it will release its financial results for Q4 and the full year 2025 on February 26, 2026. The company will hold a conference call to discuss these results and its business outlook. This event highlights Nautilus's ongoing developments in the field of proteomics.
Read more →NAUTOMICS IN SPACE – Interview with Professor Afshin Beheshti on Translating Proteomics
In a recent interview, Professor Afshin Beheshti discusses the intersection of spaceflight and biology, highlighting how space research can inform human health. He addresses biological challenges faced during spaceflight and the importance of omics studies. The conversation also touches on gaps in current research and the potential of AI in advancing these studies.
Read more →NAUTAdvantages of Iterative Mapping – Comprehensive proteomic analysis
Nautilus introduces Iterative Mapping, a novel approach for comprehensive proteomic analysis. This method excels in identifying and quantifying proteins at the single molecule level, addressing challenges faced by traditional techniques. It utilizes machine-learning algorithms to enhance accuracy and can detect subtle differences in protein abundance, making it a significant advancement in the field.
Read more →NAUT▼ -5.8%on this newsshared move
Nautilus Biotechnology and Weill Cornell Medicine-Qatar Collaborate with The Michael J. Fox Foundation to Advance Single-Molecule Proteomics Research in Parkinson’s Disease
Nautilus Biotechnology has partnered with Weill Cornell Medicine-Qatar and The Michael J. Fox Foundation to advance research on alpha-synuclein in Parkinson's disease. The collaboration, supported by a $1.6 million grant, aims to develop a single-molecule assay to measure various proteoforms of alpha-synuclein. This research could improve understanding of the disease and enhance biomarker development for clinical trials.
Read more →NAUTAdvantages of Iterative Mapping – Accuracy
Nautilus' Iterative Mapping method enhances proteomic analysis by ensuring comprehensive capture of proteins and accurate quantification. By analyzing single protein molecules independently, it minimizes errors associated with bulk measurements. This innovative approach aims to provide insights into biological processes, aiding in the identification of biomarkers and the development of precision medicines.
Read more →NAUTAdvantages of Iterative Mapping – Standardization and scalability
Nautilus introduces Iterative Mapping, a novel approach aimed at standardizing and scaling proteomic analyses. This method allows for uniform analysis of proteins by conjugating them to DNA nanoparticles, facilitating massive parallel analysis. By using a single set of probes for various proteins and proteoforms, it simplifies workflows and enhances reproducibility. The goal is to make proteomic analysis accessible to all labs.
Read more →NAUTAnnouncing the Iterative Mapping Early Access Program!
Nautilus Biotechnology is launching the Iterative Mapping Early Access Program in January 2026, allowing select researchers to generate single-molecule proteomic data. The program will initially offer the Nautilus Tau Proteoforms assay, focusing on tau proteoform biology, which is critical for developing biomarkers and drug targets for neurodegenerative diseases. Participants will receive support from Nautilus in designing and analyzing their experiments.
Read more →NAUTNautilus Biotechnology Launches Early Access Program for Novel Single-Molecule Proteomics Platform, Starting with Tau Proteoforms Assay
Nautilus Biotechnology has launched an Early Access Program for its novel proteomics platform, starting with a tau proteoforms assay aimed at Alzheimer’s research. This initiative allows selected researchers to utilize Nautilus' Iterative Mapping method, which provides high-resolution insights into protein variations. The company emphasizes that its platform delivers unique capabilities compared to traditional proteomics methods. Initial validation and positive feedback from research partners demonstrate the platform's potential impact on advancing neurodegenerative biology studies.
Read more →NAUTReflections on Proteomics – 2025 Year-End Wrap-Up
The article reflects on key developments in proteomics during 2025, highlighting insights from the World HUPO 2025 conference. Key trends include a shift towards application-focused research, increased recognition of proteoforms, and the rise of multiomics studies. Additionally, there is a notable integration of AI into proteomics workflows. Predictions for 2026 are also shared.
Read more →NAUT▼ -5.1%on this newsshared move
Proteomics and One Health – Bridging animal, human, and ecosystem health by studying the proteome
The article discusses the importance of proteomics in understanding health through the One Health approach, which integrates human, animal, and environmental health. It highlights research by Professor Jennifer Geddes-McAlister on cryptococcal infections and antifungal resistance, as well as advancements in molecular pharming. The Nautilus Proteome Analysis Platform aims to improve accessibility and efficiency in proteomics research.
Read more →NAUTQuantifying proteins and proteoforms with Iterative Mapping on the Nautilus Platform
Nautilus Biotechnology has introduced Iterative Mapping, a groundbreaking method for quantifying proteins and proteoforms across the entire proteome. This technique utilizes massive single-molecule arrays to capture billions of protein molecules, employing fluorescent probes for precise identification. The method's machine learning algorithms facilitate robust quantification, marking a significant advancement in proteomics.
Read more →NAUTLife at Nautilus Interview with Carlos Flores
Carlos Flores, a Lead Production Engineer at Nautilus, discusses his role in ensuring the quality and timely production of flow cells for protein analysis. He emphasizes the importance of communication and decision-making in a fast-paced environment. Carlos expresses excitement about the potential impacts of Nautilus's platform on life sciences and his aspirations to start a community-focused business in the future.
Read more →NAUT▲ +5.2%on this news
Nautilus at HUPO 2025 – Redefining proteomics with single-molecule Iterative Mapping
Nautilus Biotechnology presented its innovative Iterative Mapping technology at HUPO 2025 in Toronto, emphasizing its ability to enhance proteomic analysis by providing both breadth and detail. Professor Birgit Schilling showcased novel data on tau proteoforms in Alzheimer's research, marking a significant milestone for the Nautilus Platform. The positive reception from the audience underscored the platform's potential to advance understanding in proteomics.
Read more →NAUT▲ +6%on this news· ran to +21% by day 3
Hosts, Microbes, Molecular Pharming, and More with Professor Jennifer Geddes-McAlister
In a recent episode of Translating Proteomics, Professor Jennifer Geddes-McAlister discusses her research on host-microbe interactions and molecular pharming. She highlights the significance of a systems biology perspective in understanding these interactions and shares insights about the upcoming Human Proteome Organization conference. Additionally, she promotes her initiative, 'Moms in Proteomics,' aimed at supporting women in the field.
Read more →NAUTNautilus’ AI-ready data may improve multiomic analyses
Nautilus is advancing proteomics by integrating AI-ready data to enhance multiomic analyses. Their Iterative Mapping technology aims to provide accurate protein measurements, facilitating clearer connections between genomic, transcriptomic, and proteomic data. The company is also focused on standardizing proteomic data to improve AI-based analysis, ultimately aiming to revolutionize biomedicine and drug development.
Read more →NAUT▲ +39.1%on this newsshared move
Nautilus Biotechnology Reports Successful Installation and Testing of its First Field Evaluation Unit at the Buck Institute for Research on Aging
Nautilus Biotechnology has successfully installed its first external field evaluation unit at the Buck Institute for Research on Aging. This milestone allows independent labs to access Nautilus' single-molecule proteomics platform, generating reproducible data on tau proteoforms related to neurodegenerative diseases. The collaboration aims to advance research on Alzheimer's disease, with initial findings set to be presented at the 2025 HUPO World Congress.
Read more →NAUTWhy is Nautilus data well-suited for AI workflows?
Nautilus is developing a next-generation proteomics platform that utilizes Iterative Mapping to provide high-quality, single-molecule protein counts. The platform's design allows for the generation of rich, nuanced data that is ideal for AI integration. This capability aims to enhance multiomic analyses and improve the understanding of biological functions. Empirical evidence supports the precision and reproducibility of the data produced.
Read more →NAUT▲ +5.9%on this newsshared move
Nautilus Biotechnology Reports Third Quarter 2025 Financial Results
Nautilus Biotechnology reported its financial results for Q3 2025, highlighting a 19% reduction in operating expenses and a net loss of $13.6 million. The company is focused on launching its early access program for Tau proteoforms in 2026, aiming for full commercialization by late 2026. Nautilus currently holds $168.5 million in cash and investments.
Read more →NAUT▲ +6.6%on this newsshared move
Why does proteomics need AI?
The article discusses the critical role of AI in advancing proteomics, emphasizing the need for better data to train biological models. It highlights the complexity of proteins and the limitations of current technologies in accurately measuring proteomic variations. Nautilus aims to provide AI-ready data that can improve multiomic analyses and enhance our understanding of biological functions.
Read more →NAUTIterative Mapping FAQ
Nautilus Biotechnology's Iterative Mapping is a groundbreaking method for quantifying proteins and proteoforms across the entire proteome. This technique utilizes single-molecule arrays and machine learning algorithms to achieve high sensitivity and reproducibility. Recent demonstrations have shown its effectiveness in quantifying tau proteoforms, and the company is actively seeking collaborations for research applications.
Read more →NAUTNautilus Biotechnology to Announce Third Quarter 2025 Financial Results on October 28, 2025
Nautilus Biotechnology, Inc. is set to announce its financial results for the third quarter of 2025 before the market opens on October 28, 2025. The announcement will be followed by a conference call at 5:30 a.m. Pacific Time, where management will discuss the results and future outlook. Nautilus focuses on developing a platform technology aimed at unlocking the complexity of the proteome, which is integral to advancements in health and medicine.
Read more →NAUTIterative Mapping makes a splash – Nautilus in the News
Nautilus Biotechnology has garnered significant attention following the release of its preprint on Iterative Mapping of tau proteoforms. The collaboration with the Allen Institute aims to enhance understanding of Alzheimer's disease progression. The technology is positioned as a key player in advancing precision medicine through the study of proteoforms, with positive feedback from industry experts.
Read more →NAUT▲ +11%on this news
Applications of proteomics in cancer – Round up September 2025
The article discusses advancements in cancer research through proteoform analysis, emphasizing its potential in precision medicine. It highlights the importance of understanding proteoforms in cancer signaling and therapy responses. The update includes new sections in the Proteomics and cancer eBook, inviting collaboration and further exploration of these findings.
Read more →NAUTInvestor presentation: Unlocking the power of the proteome to revolutionize biomedicine
Nautilus Biotechnology's CEO Sujal Patel and CFO Anna Mowry presented at the Q3 Investor Summit, emphasizing the need for their innovative platform to enhance drug development and precision medicine. The Nautilus Platform aims to provide comprehensive proteomic analysis with high reproducibility and sensitivity. The presentation showcased the potential of this technology to transform biomedicine.
Read more →NAUTMaking proteoforms mainstream with the Consortium for Top-Down Proteomics
The article discusses the significance of proteoforms in biological research and precision medicine. It highlights the challenges faced in the adoption of proteoform-centric studies, particularly the complexity of top-down mass spectrometry (TDMS). The Consortium for Top-Down Proteomics (CTDP) conference revealed a need for complementary technologies and a potential rebranding to the 'Proteoform Alliance' to enhance understanding and collaboration in the field.
Read more →NAUTFunctional differences in the KRAS proteoform landscape
The article discusses the exploration of KRAS proteoforms and their potential implications in cancer treatment. Recent research highlights the identification of novel truncated KRAS proteoforms that may alter signaling pathways. The study emphasizes the importance of proteoform analysis for understanding biological processes and developing precision medicine strategies. Future work aims to link specific proteoform profiles to clinical outcomes.
Read more →NAUTBenefits and needs of proteomics science communication
The article discusses the importance of science communication in proteomics, highlighting the efforts of Ben Orsburn and Ben Neely through their podcast, The Proteomics Show. They aim to raise awareness about the significance of proteins in biological functions and advocate for more educational initiatives in the field. Their discussions reveal the diverse backgrounds of scientists and the need for better representation of proteomics in popular culture.
Read more →NAUTNautilus Biotechnology to Participate in Upcoming September Investor Conferences
Nautilus Biotechnology, Inc. announced its participation in upcoming investor conferences. The company, known for its innovative single-molecule protein analysis platform, aims to enhance access to proteomics. Interested parties can access live and archived webcasts of the presentations on their website. Nautilus is focused on advancing human health through its technology.
Read more →NAUTLife at Nautilus Interview with Nicole Newland – Senior HR Operations Generalist
Nicole Newland, Senior HR Operations Generalist at Nautilus, emphasizes her passion for connecting with people and improving HR processes. With a background in psychology, she effectively navigates recruitment and employee relations. Her journey from recruiting to a full-time HR role showcases her commitment to enhancing employee well-being and fostering positive workplace relationships.
Read more →NAUTExcitement for Iterative Mapping of proteoforms at AAIC 2025
At AAIC 2025, Nautilus Biotechnology showcased its Iterative Mapping technology, which offers a new approach to proteomics. The platform received positive feedback from researchers, who are eager to integrate it into their studies on tau and Alzheimer's disease. Nautilus aims to enhance understanding of tau biology and improve therapeutic outcomes through collaborations.
Read more →NAUTInsights from Iterative Mapping of tau proteoforms – bioRxiv preprint round up
Nautilus Biotechnology's recent preprint discusses the use of Iterative Mapping to analyze tau proteoforms, which are linked to cognitive decline in Alzheimer's disease. The study highlights the method's ability to provide single-molecule resolution and its potential to reveal new insights into disease mechanisms. Preliminary data suggests a connection between specific tau proteoforms and disease severity, paving the way for advancements in drug and biomarker development.
Read more →NAUTParag answers questions about the Nautilus Proteome Analysis Platform – Video
Nautilus Biotechnology has released a video featuring Parag discussing the Nautilus Proteome Analysis Platform. The video addresses various aspects of the platform, including its Iterative Mapping methodology, probe design, detection limits, and accessibility for researchers. This initiative aims to engage the proteomics community and provide insights into the platform's capabilities.
Read more →NAUTNautilus Biotechnology Reports Second Quarter 2025 Financial Results SEATTLE, WA
Nautilus Biotechnology reported its financial results for the second quarter of 2025, highlighting significant advancements in its proteome analysis platform. The company experienced a reduction in operating expenses and a smaller net loss compared to the previous year. Key milestones included the publication of a scientific manuscript featuring novel data and new collaborations with research institutes to study Tau proteoforms in Alzheimer's disease models. Despite these achievements, Nautilus continues to face challenges with its platform's commercialization and further development needs.
Read more →NAUTTranslating Proteomics “Ask me anything” episode featuring special guest Don Kirkpatrick
In a recent episode of Translating Proteomics, hosts Parag and Andreas, along with guest Don Kirkpatrick, explored various topics related to plasma proteomics. They discussed the needs in the field, the influence of lifestyle on the proteome, and how Nautilus's technology is advancing research on tau and Alzheimer's disease. The episode emphasizes the importance of proteomics in drug development.
Read more →NAUTNautilus Biotechnology Announces Agreement with the Allen Institute, Further Validating its Approach to Single-Molecule Proteomics
Nautilus Biotechnology has partnered with the Allen Institute to explore the role of tau protein in Alzheimer's disease using its single-molecule proteomics method. This collaboration aims to identify and characterize tau proteoforms, which could lead to breakthroughs in diagnostics and treatment. The agreement highlights the significance of Nautilus's Iterative Mapping approach in advancing proteomic research.
Read more →NAUTProteoform profiles may differentiate disease phenotypes
The article discusses how specific proteoform profiles can differentiate between various phenotypes of Alzheimer's Disease and Related Dementias (ADRD). It highlights the potential of these profiles to inform the development of precision medicines and improve patient care. The findings suggest that certain proteoforms may be associated with disease severity, paving the way for targeted therapeutic strategies.
Read more →NAUTProteoforms are not random – evidence for order in the creation of proteoforms
The article discusses the advancements in understanding tau proteoforms using Iterative Mapping. This method allows for detailed analysis of phosphorylation patterns and proteoform mixtures, revealing non-random creation processes. The findings suggest that specific proteoforms may play crucial roles in biological functions and disease, paving the way for targeted drug development.
Read more →NAUT▼ -8.6%on this newsshared move
Nautilus Biotechnology to Announce Second Quarter 2025 Financial Results on July 31, 2025
Nautilus Biotechnology, Inc. announced that it will release its financial results for the second quarter of 2025 on July 31, 2025, before the market opens. The company plans to host a webcast conference call to discuss these results along with business developments and their future outlook. Nautilus is known for its single-molecule protein analysis platform aimed at advancing proteomics for improved health outcomes.
Read more →NAUTIterative Mapping provides in-depth views of proteoform groups
Nautilus has introduced Iterative Mapping, a new method for analyzing proteoforms, which are functional variants of proteins. This approach allows researchers to achieve detailed proteoform group resolution, potentially aiding in the development of therapeutics for neurodegenerative diseases. The technology offers unique insights into the proteome that are not possible with traditional methods.
Read more →NAUTIterative Mapping of proteoforms may reveal novel biology and new drug targets
Nautilus is advancing proteoform analysis through its Iterative Mapping method, which enhances the understanding of protein variants and their roles in diseases like Alzheimer's. This approach may lead to new therapeutic targets and diagnostics by revealing the molecular mechanisms underlying various pathologies. Preliminary studies indicate high accuracy and sensitivity in measuring tau proteoforms, suggesting significant potential for drug development.
Read more →NAUTLife at Nautilus interview with Juanfeng Sun
Juanfeng Sun, an Engineer III at Nautilus, discusses his journey from chemical engineering to biotech. He highlights the importance of long-term goals in product development and the excitement of working in proteomics. Sun emphasizes the value of cross-functional collaboration and the fulfillment that comes from contributing to groundbreaking work aimed at addressing intractable diseases.
Read more →NAUTBiomarkers Are Changing Everything – A New Era in Alzheimer’s Research
Dr. Sarah DeVos discusses advancements in Alzheimer's research, highlighting new biomarkers that allow for earlier diagnosis and the potential for personalized therapies. Recent FDA-approved blood tests and therapeutics targeting amyloid plaques are paving the way for improved patient outcomes. However, existing treatments do not halt disease progression, indicating the need for further research.
Read more →NAUTLife at Nautilus interview with Lisen Wang – Senior Staff Engineer
Lisen Wang, a Senior Staff Engineer at Nautilus, discusses his role in optimizing the Nautilus TM Proteome Analysis Platform. He emphasizes the importance of engineering in understanding biology at the molecular level and highlights the collaborative environment at Nautilus. Wang enjoys the challenges of measuring the proteome and is dedicated to improving user experiences with the platform.
Read more →NAUTProteoforms, metastasis, and cancer therapy responses – Applications of proteomics in cancer
The article discusses the significance of proteoforms in cancer research, emphasizing their role in cancer cell signaling and treatment responses. It reviews studies demonstrating how proteoform diversity can influence therapeutic outcomes and highlights the need for advanced proteomics techniques to better understand these variations. The findings suggest that proteoform analysis could lead to new biomarkers and targeted therapies.
Read more →NAUT▲ +9.4%on this news
Spatial Proteomics with Fiona Ginty Ph.D. – Translating Proteomics
In a recent episode of Translating Proteomics, host Parag Mallick interviews Dr. Fiona Ginty, a Senior Principal Scientist at GE Healthcare. They discuss the significance of spatial proteomics in precision diagnostics, Dr. Ginty's career journey, and the future of spatial biology. The episode also covers innovative technologies and collaborative projects in the field.
Read more →NAUT▲ +5.6%on this newsshared move
Nautilus Biotechnology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
Nautilus Biotechnology, Inc. will participate in the Goldman Sachs 46th Annual Global Healthcare Conference on June 10, 2025. The event will feature a fireside chat with the company's management, which will be accessible via a live and archived webcast. Nautilus aims to innovate in the field of proteomics through its unique platform technology.
Read more →NAUTProteomics and the food of the future
The article discusses the potential applications of proteomics in food production and safety. It highlights how next-generation proteomics platforms can improve food quality, enhance safety measures, and aid in the development of new food products. The hosts of the podcast emphasize the importance of understanding food qualities and how proteomics can transform the food industry.
Read more →NAUTProteoforms and EGFR signaling – Applications of proteomics in cancer
The article discusses the critical role of proteoforms in EGFR signaling and their implications in cancer. It highlights research indicating that distinct modification patterns on EGFR proteoforms can significantly influence signaling outcomes. The findings suggest that understanding these proteoforms may lead to advancements in precision medicine targeting the EGFR pathway.
Read more →NAUTLife at Nautilus Interview with Denise Miller – Associate Director of Software Engineering
Denise Miller, Associate Director of Software Engineering at Nautilus, shares her journey and passion for merging software engineering with biology. Her personal experience with cancer has motivated her to develop technologies aimed at curing diseases. Nautilus is characterized by a collaborative culture where scientists are involved in product development, enhancing the platform's effectiveness.
Read more →NAUTUnlocking the potential of plasma proteomics
The article discusses the transformative potential of plasma proteomics in biomarker discovery, highlighting both its opportunities and challenges. Experts from Nautilus emphasize the complexity of the plasma proteome and the need for advanced detection technologies. Innovations such as longitudinal sampling and multiomic approaches are presented as promising strategies to improve diagnostics. Despite significant hurdles, ongoing advancements aim to refine plasma proteomics for actionable insights.
Read more →NAUT▲ +8%on this newsshared move
Nautilus Biotechnology Reports First Quarter 2025 Financial Results SEATTLE, WA
Nautilus Biotechnology, Inc. reported its financial results for Q1 2025, showing a net loss of $16.6 million, an improvement from $18.7 million during the same quarter last year. Operating expenses decreased to $18.8 million, reflecting the company's focus on cost optimization. The company is progressing with its Tau proteoform assay, aiming to revolutionize research into Alzheimer's disease. Nautilus emphasizes that the product is not yet commercially available and further validation is required before launch.
Read more →NAUTIntro to Proteomics – Translating Proteomics
The episode of Translating Proteomics introduces the field of proteomics, covering key questions, methods, and challenges. It emphasizes the significance of measuring the proteome for insights into biological functions and highlights new areas of study such as spatial and single-cell proteomics. The discussion serves as a valuable resource for newcomers to the field.
Read more →NAUT▼ -6.1%on this newsshared move
Nautilus Biotechnology to Announce First Quarter 2025 Financial Results on April 29, 2025
Nautilus Biotechnology, Inc. has announced that it will report its financial results for the first quarter of 2025 on April 29, 2025, before market open. The company will also hold a conference call to discuss these results along with business developments and its outlook. This announcement is part of Nautilus's ongoing efforts to advance its single-molecule proteome analysis platform and its mission to enable advancements in human health and medicine.
Read more →NAUTLife at Nautilus Interview with Michael Darcy Ph.D. – Senior Scientist
Michael Darcy, a Senior Scientist at Nautilus, shares his journey in science and engineering, emphasizing his passion for understanding complex systems. He highlights the innovative work at Nautilus, focusing on measuring the proteome and leveraging DNA nanotechnology. Darcy appreciates the collaborative and optimistic environment at Nautilus, which fosters exploration and problem-solving.
Read more →NAUT▼ -6.1%on this news
How AI is Changing the Future of Biotech Research
The article discusses the transformative role of AI in biotech research, highlighting insights from industry leaders on how AI can analyze complex biological data and automate laboratory processes. It emphasizes the challenges posed by biological data complexity and the potential of AI agents to enhance experimental design and execution. The future of biological research is depicted as increasingly reliant on AI technologies.
Read more →NAUT▼ -15.8%on this newsshared move
Proteomics Podcast Crossover – The Proteomics Show
The article discusses a crossover episode of The Proteomics Show featuring Parag Mallick, who shares his journey in proteomics and advocacy for open data sharing. The podcast aims to connect listeners with leading figures in the proteomics community. It encourages further exploration of the show's extensive interview archive.
Read more →NAUTUS HUPO 2025 – Key Takeaways, Trends, and Future Directions for Proteomics
The hosts of Translating Proteomics discussed key takeaways from the 2025 US HUPO conference, emphasizing the increasing use of diverse proteomics platforms and advancements in multiomics. They expressed enthusiasm for future developments in proteomics and shared their hopes for the next conference. The conversation highlighted the growing importance of proteoforms in the field.
Read more →NAUTProteoforms and Alzheimer’s disease
Recent discussions at HUPO conferences highlight the significance of proteoforms in Alzheimer's disease. Research indicates that tau and amyloid beta proteoforms could serve as biomarkers for diagnosis and treatment. Unique PTM signatures may unlock precision medicine approaches, while advancements in proteomics technology promise to enhance understanding and therapeutic strategies for Alzheimer's.
Read more →NAUTTau proteoforms as potential drivers of cognitive decline – Applications of proteomics in neuroscience
The article discusses the role of tau proteoforms in Alzheimer's disease, emphasizing their association with cognitive decline. Research indicates that specific tau proteoform profiles correlate with the rate of cognitive decline in patients. Depleting tau proteoforms linked to seeding may offer a promising therapeutic strategy. The development of precision medicines targeting these proteoforms could enhance treatment outcomes.
Read more →NAUT▼ -6.2%on this news
Life at Nautilus interview with Winnie Leung – Software Engineer
Winnie Leung, a Software Engineer at Nautilus, discusses her role in developing software tools for image analysis of proteins. She highlights the importance of automation in processing large datasets and the collaborative environment at Nautilus. Winnie expresses excitement about future advancements in proteomics and the potential impact on Alzheimer's research.
Read more →NAUT▼ -5%on this news
Nautilus at US HUPO 2025 – Bringing the proteome into focus with the Nautilus Proteome Analysis Platform
At US HUPO 2025, Nautilus presented groundbreaking data from its Proteome Analysis Platform, emphasizing its potential to transform biological and disease understanding. The platform's ability to measure various tau proteoforms was highlighted, showcasing its application in Alzheimer's research. Researchers expressed keen interest in leveraging this technology for their studies, indicating a promising future for Nautilus.
Read more →NAUTAmyloid beta proteoforms and Alzheimer’s Disease – Applications of proteomics in neuroscience
Recent advancements in proteomics are shedding light on the role of amyloid beta proteoforms in Alzheimer's disease. Research indicates that these proteoforms are diverse and may significantly influence the development and progression of the disease. While current treatments targeting amyloid beta can slow cognitive decline, they do not prevent it, highlighting the need for further investigation into the specific roles of these proteoforms in Alzheimer's pathology.
Read more →NAUT▼ -18.2%on this newsshared move
Nautilus Biotechnology Reports Fourth Quarter and Fiscal Year 2024 Financial Results SEATTLE, WA
Nautilus Biotechnology reported its financial results for Q4 and the fiscal year 2024, showing stable operating expenses but a notable increase in net loss. The company anticipates launching its proteome analysis platform in late 2026 while managing expenses and reducing headcount to align resources more effectively. Despite innovations and advancements, the overall financial performance indicates challenges, particularly with higher losses compared to the previous year.
Read more →NAUTScience Communication and Proteomics – Benefits, Barriers, and Solution with Ben Neely and Ben Orsburn
In a recent episode of Translating Proteomics, host Parag Mallick interviews Ben Neely and Ben Orsburn about the significance of communication in the field of proteomics. They discuss their experiences hosting 'The Proteomics Show' and how it has influenced their research. The conversation also addresses barriers to the broader acceptance of proteomics in life sciences and public awareness.
Read more →NAUTNautilus Biotechnology to Participate in the TD Cowen 45th Annual Healthcare Conference
Nautilus Biotechnology, Inc. is set to participate in the TD Cowen 45th Annual Healthcare Conference. Scheduled for March 3, 2025, management will take part in a fireside chat, which can be accessed through the company website. The participation highlights Nautilus' advancements in the field of proteomics and its commitment to improving human health.
Read more →NAUTLife at Nautilus Interview with Irene Sparck -Leveraging the language of business to help Nautilus grow
Irene Sparck, Senior Manager of Accounting at Nautilus, discusses her career transition from urban planning to accounting. She highlights the actionable insights accounting provides for business efficiency and decision-making. Sparck expresses her motivation from Nautilus's mission to improve lives and the supportive team environment. Her future goal is to lead accounting functions in an organization.
Read more →NAUTNautilus Biotechnology to Announce Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025
Nautilus Biotechnology, Inc. plans to announce its fourth-quarter and full-year financial results for 2024 on February 27, 2025, before the market opens. The announcement will be accompanied by a conference call scheduled for 5:30 a.m. Pacific Time, where management will discuss results and future outlook. Nautilus focuses on revolutionizing proteomics through its unique single molecule protein analysis platform.
Read more →NAUTThe Future of Food in a Proteomics World: Translating Proteomics Episode 16
In the latest episode of Translating Proteomics, hosts Parag Mallick and Andreas Huhmer explore the transformative role of proteomics in food interactions. They discuss its applications in improving food quality, safety, and the development of new food products. The episode also touches on how proteomics can aid in plant and animal breeding, and its implications for food authenticity and security.
Read more →NAUTTau proteoforms as potential drivers of precision medicine – Applications of proteomics in neuroscience
Recent research highlights the potential of tau proteoforms in diagnosing Alzheimer's disease and other tauopathies. By mapping disease-specific proteoforms, researchers aim to develop precise biomarkers that can distinguish between different tauopathies. This could lead to more effective precision medicine strategies targeting the molecular roots of these diseases.
Read more →NAUTCombating the Reproducibility Crisis in Computational Proteomics – Translating Proteomics Episode 15
In the latest episode of Translating Proteomics, Nautilus Biotechnology co-hosts discuss the reproducibility crisis in biology, particularly in computational proteomics. They highlight the challenges of replicating multiomics research and propose actionable steps to improve reproducibility. Key recommendations include better documentation practices and advocating for funding to support reproducibility efforts.
Read more →NAUTLife at Nautilus Interview with Vivek Budamagunta, Ph.D., Scientist II
Vivek Budamagunta, a Scientist II at Nautilus Biotechnology, shares his passion for aging research and the innovative work being done at Nautilus. He emphasizes the importance of their platform in advancing biological research and its potential to improve lives. Vivek appreciates the collaborative environment and the resources available, which enhance his research capabilities.
Read more →NAUTUsing Proteomics to Advance Drug Development – Translating Proteomics Episode 14
In the latest episode of Translating Proteomics, Nautilus Biotechnology co-hosts discuss the application of proteomics in drug development. Key topics include the role of proteomics in pre-clinical models, patient selection, and the importance of choosing appropriate endpoints in clinical trials. The episode emphasizes how proteomics can improve the efficiency and effectiveness of clinical research.
Read more →NAUTThe evolving concept of druggability
The article discusses how advances in proteomics are redefining the concept of druggability in drug development. Traditionally focused on easily identifiable enzymes, the field is now expanding to include low-abundance proteins and their interactions. Experts argue that this shift will enhance drug discovery and enable more personalized treatments. The potential for new proteomics tools to unlock previously undruggable targets is emphasized.
Read more →NAUT3 Examples of Exciting Proteomics Research in 2024 – Translating Proteomics Year-end Special
The year-end episode of Translating Proteomics features notable 2024 research in proteomics, including studies on drug impacts on protein expression, aneuploidy tolerance in yeast, and advancements in nanopore sequencing technology. These studies illustrate the diverse applications and potential of proteomics in understanding biological systems and developing new therapies.
Read more →NAUTWebinar – Expanding Proteomic Horizons with Single-Molecule Proteome Analysis
Nautilus Biotechnology hosted a webinar featuring Co-Founder Parag Mallick discussing their innovative platform for single-molecule proteome analysis. The session highlighted the latest data on tau proteoforms, emphasizing the platform's potential to transform the field of proteomics. Viewers can access the on-demand webinar for detailed insights.
Read more →NAUTThe 2024 Nobel Prize in Chemistry points to a new protein-powered era of biological discovery
The 2024 Nobel Prize in Chemistry was awarded to David Baker, Demis Hassabis, and John Jumper for their groundbreaking work in protein design and structure prediction. Their contributions emphasize the importance of proteins in biological discovery and the integration of proteomics with structural biology. This synergy is expected to enhance our understanding of protein functions and interactions, paving the way for innovative applications in biology.
Read more →NAUTNautilus in the News – GenomeWeb: Nautilus Proteomics Platform Could Bring New Depth to Proteoform Analyses
Nautilus presented innovative tau proteoform data at the HUPO 2024 conference, as reported by GenomeWeb. Experts Neil Kelleher and Sally Temple discussed the significant implications of this new data for proteoform analyses. Temple, who is also a collaborator with Nautilus, emphasized the transformative potential of these findings in the field.
Read more →NAUTHow AI is Changing the World of Biotech – Translating Proteomics Episode 13
In the latest episode of Translating Proteomics, host Parag Mallick explores the integration of AI and machine learning in biotechnology. Guests Vijay Pande and Matt McIlwain share insights on how these technologies are revolutionizing the industry, discussing advancements, applications by founders, and future prospects. The episode highlights the importance of structured data and algorithmic progress in driving innovation.
Read more →NAUTDriving marketing success with a focus on people and trust – Interview with Nautilus Chief Marketing Officer Ken Suzuki
Ken Suzuki has joined Nautilus as Chief Marketing Officer, bringing over 24 years of experience from Agilent Technologies. He emphasizes the importance of trust and relationships in marketing, aiming to leverage these principles to successfully launch Nautilus's novel proteome analysis platform. Suzuki believes that focusing on customer success will be key to the company's growth and innovation in proteomics.
Read more →NAUTHow Proteomics is Opening a New Era of Alzheimer’s Research – Translating Proteomics Episode 12 Featuring Sarah DeVos
In the latest episode of Translating Proteomics, Dr. Sarah DeVos discusses the advancements in Alzheimer's research, focusing on molecular diagnostics and recent drug approvals. The conversation highlights the potential of proteomics in developing early-stage biomarkers and improving diagnostic tools. DeVos shares insights on the future of Alzheimer's research and the challenges faced in the field.
Read more →NAUTWhy single-protein biomarkers don’t cut it – From single notes to whole chords in biomarker discovery
Nautilus Biotechnology discusses the challenges and advancements in biomarker discovery on their podcast. Co-founders Parag Mallick and Andreas Huhmer emphasize the need to move beyond single-protein biomarkers and adopt new technologies for better detection. They advocate for proactive sampling methods and a deeper understanding of biomarker biology to improve clinical applications.
Read more →NAUTSelect Nautilus presentations from HUPO 2024
Nautilus Biotechnology presented two key talks at HUPO 2024 in Dresden, Germany. The first, by Andreas Huhmer, focused on quantitative assessments of tau proteoforms using the Nautilus Proteome Analysis Platform. The second presentation by Sheri Wilcox highlighted the platform's capability to achieve a wide dynamic range for comprehensive proteome coverage.
Read more →NAUTNautilus Biotechnology Co-founder and Chief Scientist Parag Mallick, Ph.D., Honored with the Academy for Radiology and Biomedical Imaging Research’s Distinguished Investigator Award
Nautilus Biotechnology announced that co-founder and Chief Scientist Parag Mallick, Ph.D., received the prestigious 2024 Distinguished Investigator Award by the Academy for Radiology and Biomedical Imaging Research. This award honors his significant contributions to imaging research, including leadership and high-impact publications. Dr. Mallick will be inducted into the Academy's Council of Distinguished Investigators during the Radiological Society of North America's Annual Meeting in December 2024.
Read more →NAUTNautilus at HUPO 2024 – Advancing proteomics across two critical and complementary research dimensions
Nautilus Biotechnology participated in HUPO 2024, highlighting their advanced proteomics platform. They demonstrated the platform's capabilities in broadscale proteomics and targeted proteoform studies, particularly focusing on tau proteoforms related to Alzheimer's disease. The positive reception from the proteomics community suggests a readiness for next-generation technologies in biological research.
Read more →NAUTNautilus Biotechnology to Participate in the Inaugural Guggenheim Healthcare Conference
Nautilus Biotechnology, Inc. announced its participation in the inaugural Guggenheim Healthcare Conference, scheduled for November 13, 2024. The company's management will engage in a fireside chat to discuss their pioneering single-molecule protein analysis platform. Interested parties can access a live and archived webcast through Nautilus's website. This event represents a strategic opportunity for Nautilus to increase visibility and support for its innovation in proteomics.
Read more →NAUTNautilus Biotechnology Reports Third Quarter 2024 Financial Results SEATTLE, WA
Nautilus Biotechnology, Inc. has reported its financial results for the third quarter of 2024, showing a net loss of $16.4 million, slightly higher than the previous year. The company's operating expenses remained stable at $19.1 million, although increased personnel costs were noted. CEO Sujal Patel highlighted positive feedback from researchers regarding their single-molecule proteome analysis platform, which is still in development and not yet commercially available. Nautilus maintains a strong cash position of $221.2 million, supporting its ongoing research and platform development efforts.
Read more →NAUTThe Dream of Plasma Proteomics – Translating Proteomics Episode 11
In the latest episode of Translating Proteomics, hosts Parag Mallick and Andreas Huhmer explore the potential of plasma proteomics in biomarker discovery. They discuss the advantages of using plasma as a source for protein biomarkers, the challenges faced in measuring protein levels, and the future direction of plasma biomarker research. The episode emphasizes the need for advancements in methodologies to fully realize the promise of plasma proteomics.
Read more →NAUTPTMs are pixels – Proteoforms are screenshots
The article discusses the importance of proteoform analysis over isolated post-translational modifications (PTMs) in understanding protein function. It highlights how proteoforms, as single-molecule variants, provide clearer mechanistic insights into biological processes. The Nautilus Proteome Analysis Platform is presented as a key technology for advancing proteoform research, enabling higher throughput and more precise analyses.
Read more →NAUTProtein Function 201 with Kathryn Lilley – Translating Proteomics Episode 10
In the latest episode of Translating Proteomics, Nautilus Co-Founder Parag Mallick interviews Professor Kathryn Lilley about the complexities of protein function. They discuss how protein functions are influenced by various factors, including proteoforms and localization. The conversation emphasizes the need for better understanding and education surrounding these complexities to advance drug development.
Read more →NAUTBeyond the central dogma – Forging a new era of biological discovery
Nautilus Biotechnology's podcast discusses the limitations of the central dogma of biology, emphasizing the need for a more nuanced understanding of biological systems. Co-founders Parag Mallick and Andreas Huhmer argue that recent discoveries in genomics and proteomics reveal complex feedback loops that challenge the linear flow of genetic information. They advocate for advanced tools and models to better capture the intricacies of biological interactions, which could significantly impact research and medicine.
Read more →NAUTWhat is broadscale proteomics?
Broadscale proteomics, also known as discovery or untargeted proteomics, aims to quantify all proteins in a sample, allowing researchers to identify changes associated with biological phenomena. The Nautilus Proteome Analysis Platform is being developed to address challenges in measuring both high and low abundance proteins, enhancing the dynamic range of proteomic analysis. This platform promises to improve reproducibility and robustness, facilitating drug discovery and biomarker identification.
Read more →NAUTNautilus Biotechnology to Announce Third Quarter 2024 Financial Results on October 29, 2024
Nautilus Biotechnology, Inc. is set to announce its financial results for the third quarter of 2024 on October 29, 2024. The announcement will be followed by a conference call to discuss the results, business developments, and future outlook. Investors can listen to the live webcast on the company's website. Nautilus focuses on creating a platform for protein analysis to advance healthcare and medicine.
Read more →NAUTAre Proteins a Myth? With Special Guest Neil Kelleher – Translating Proteomics Episode 9
In the latest episode of Translating Proteomics, Parag interviews Neil Kelleher, a pioneer in proteoform research. They explore the significance of proteoforms, technological advancements needed for their analysis, and real-world examples demonstrating their impact, such as predicting liver transplant success. The episode emphasizes the complexity of proteoforms and their role in understanding biological functions.
Read more →NAUTUnderstanding proteoforms – Unlocking the complexity of proteins
Nautilus Biotechnology emphasizes the significance of proteoforms, which are protein variants influenced by modifications. These variants are crucial for understanding biological functions and disease mechanisms. The company highlights the need for advanced measurement tools to fully harness the potential of proteoforms in research and medicine, suggesting that future therapies could target specific proteoforms for improved precision.
Read more →NAUT▲ +5.2%on this news
AI in proteomics – Unleashing the potential of artificial intelligence in biomedicine
The article discusses the transformative potential of artificial intelligence (AI) in proteomics and biomedicine. It highlights advancements like AlphaFold, which has improved drug discovery through better protein structure understanding. However, challenges such as the need for well-curated datasets and the dynamic nature of proteins pose significant hurdles. The authors emphasize the importance of AI as a tool to assist researchers rather than replace them.
Read more →NAUTApplications of proteomics in neuroscience – Round up September 2024
Nautilus Biotechnology showcases recent advancements in proteomics applied to neuroscience. Key studies focus on Alzheimer's disease, exploring amyloid beta's role and cognitive resilience. Additionally, research on Angelman syndrome reveals insights into its progression and potential treatments. The updated Proteomics and Neuroscience eBook compiles these findings and offers further resources.
Read more →NAUTNautilus Biotechnology Appoints Mass Spectrometry Leader Ken Suzuki as Chief Marketing Officer
Nautilus Biotechnology has appointed Ken Suzuki as its Chief Marketing Officer, bringing in over 25 years of experience in product and marketing roles, predominantly at Agilent Technologies. His expertise is expected to enhance Nautilus' efforts in bringing their Proteome Analysis Platform to market, which aims to advance the field of proteomics. CEO Sujal Patel emphasized the strategic importance of Suzuki's appointment as the company prepares to innovate in protein analysis technologies. However, Nautilus still faces challenges, including the need for product validation and potential delays in commercial availability.
Read more →NAUT▲ +5.6%on this news
Moving from snapshots to movies to capture the dynamic nature of the proteome
Nautilus Biotechnology emphasizes the need for dynamic perspectives in proteomics, moving beyond static snapshots to capture the proteome's complexity. Co-founders Parag Mallick and Andreas Huhmer discuss the technological advancements required to achieve this, including higher sample rates and better computational tools. They believe this shift will enhance our understanding of biological processes and lead to precision medicine.
Read more →NAUTFrom the future plate to hardier plants – How proteomics could transform life as we know it
The article discusses the transformative potential of proteomics in various fields, including agriculture and therapeutics. Nautilus Biotechnology's innovations aim to analyze the full range of proteomes, which could lead to breakthroughs like drought-resistant plants and improved pest control. The need for accessible and affordable proteomics tools is emphasized as crucial for advancing these applications.
Read more →NAUT▲ +8.3%on this news
Spatiotemporal changes to the proteome in Angelman syndrome – Applications of proteomics in neuroscience
The article discusses recent findings on Angelman syndrome, focusing on the role of proteomics in understanding the disorder. Research by Pandya et al. highlights the importance of early reinstatement of the UBE3A gene for effective physiological rescue. Additionally, transketolase has been identified as a key protein potentially involved in the disease's pathology. The findings suggest further research is needed to explore therapeutic interventions.
Read more →NAUTThe future of proteomics – How converging trends will revolutionize biology and medicine
Nautilus Biotechnology highlights the rapid advancements in proteomics, driven by new technologies and the need for multiomic insights in precision medicine. The field is poised for breakthroughs, with increasing educational interest and the potential for significant medical and biological applications. However, further standardization and innovative naming conventions are necessary to fully realize proteomics' potential.
Read more →NAUTAlzheimer’s insights from amyloid beta expression in nematodes – Applications of proteomics in neuroscience
Recent research by Anderton et al. (2024) explores the role of amyloid beta (Aβ) in Alzheimer's disease using C. elegans models. They discovered a core insoluble proteome that may be influenced by Aβ aggregation, potentially affecting disease progression. Their findings suggest that targeting these proteins could lead to new therapeutic strategies for Alzheimer's and other age-related diseases.
Read more →NAUTNautilus Biotechnology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
Nautilus Biotechnology, Inc. announced its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference set for September 4, 2024, in New York. Management will engage in a fireside chat, which highlights the company's growing presence in the healthcare sector. The event indicates Nautilus's efforts to enhance investor relations and promote its innovative proteome analysis platform. Interested individuals can access a live and archived webcast of the presentation on the company's website.
Read more →NAUTApplications of proteomics in cancer – Round up August 2024
Nautilus Biotechnology highlights the transformative role of proteomics in cancer research, emphasizing its ability to uncover complex biological mechanisms beyond genetic mutations. Recent studies have demonstrated how proteomics can inform precision medicine and enhance understanding of tumor microenvironments. The company has compiled a range of resources, including blog posts and an eBook, to showcase these advancements.
Read more →NAUTAnimation – Unlocking the potential of proteomics to fuel cancer research
Nautilus Biotechnology highlights the importance of proteomics in cancer research. The article discusses how proteomic changes can lead to resistance against therapies, the influence of the tumor microenvironment, and the role of proteomic differences in therapeutic responses. This approach aims to enhance precision medicine by identifying new biomarkers and treatment strategies.
Read more →NAUTFinding proteomic drivers of cognitive resilience in Alzheimer’s – Applications of proteomics in neuroscience
A recent study by Hurst et al. (2023) utilized proteomic analysis to investigate cognitive resilience in Alzheimer's disease. They identified the NRN1 protein as a key factor that may protect against cognitive decline despite the presence of amyloid beta plaques. The research highlights the importance of cognitive resilience and suggests potential therapeutic targets for Alzheimer's treatment.
Read more →NAUTNautilus Biotechnology Reports Second Quarter 2024 Financial Results SEATTLE, WA
Nautilus Biotechnology reported its second quarter 2024 financial results, demonstrating progress on development goals for its unique proteome analysis platform. The company experienced a net loss of $18 million, up from $15.8 million year-over-year, while operating expenses increased by 9%. Despite the losses, Nautilus holds substantial cash reserves which it can leverage for development and operational support.
Read more →NAUTApplications of single-molecule proteomics – studying the tumor microenvironment
The article discusses the importance of studying the tumor microenvironment in cancer research, highlighting recent advancements in proteomics. Researchers have used mass spectrometry to analyze immune cell types within tumors, revealing significant differences across various cancer subtypes. The potential of single-molecule proteomics is emphasized for its sensitivity and ability to identify specific proteoforms, which could lead to more targeted cancer therapies.
Read more →NAUTApplications of proteomics in cancer – How proteomics complements genomic studies of colorectal cancer metastasis
A recent study from the Roehrl Lab published in Cell Reports explores the role of proteomics in understanding colorectal cancer (CRC) metastasis. The researchers employed a multiomics approach to identify distinct proteomic signatures in primary and metastatic CRC samples. This study highlights the potential of proteomics to inform treatment strategies and improve cancer diagnostics.
Read more →NAUTApplications of proteomics in cancer – Identifying potential precision medicines for cancer
Recent research by Liu et al. 2024 highlights the application of proteomics in identifying potential therapeutic targets in small cell lung cancer (SCLC). The study reveals biomarkers associated with patient survival and categorizes SCLC into four subtypes with distinct therapeutic vulnerabilities. These findings underscore the promise of proteomics in developing precision medicines tailored to individual patient needs.
Read more →NAUTApplications of proteomics in cancer – Exploring the relationship between senescence and tumor clearance
Recent research by Chen et al. at Memorial Sloan Kettering explores the role of senescence in tumor clearance, revealing that senescent cells can either aid in tumor regression or contribute to relapse. Their findings emphasize the importance of interferon gamma signaling in recruiting immune cells to destroy tumors. This research may pave the way for new cancer treatments that leverage senescence.
Read more →NAUTNautilus Biotechnology to Announce Second Quarter 2024 Financial Results on July 30, 2024
Nautilus Biotechnology, Inc. has announced that it will release its financial results for the second quarter of 2024 on July 30, 2024, before the markets open. The company will hold a conference call to discuss these results, along with updates on business developments and its outlook. This session will be available to investors via a webcast on their website. Nautilus is focused on advancing the proteomics field to enhance access to crucial biological information.
Read more →NAUTAchieving Personalized Medicine With Proteomics – Translating Proteomics Episode 8
The latest episode of 'Translating Proteomics' discusses the role of proteomics in drug development and personalized medicine. Hosts Dr. Parag Mallick and Dr. Andreas Huhmer explore how proteomics can identify effective drug targets and improve the precision of drug development. They highlight the advancements in proteomics technologies that are reshaping the landscape of drug discovery.
Read more →NAUTProteoforms, the Future of Proteomics? – Translating Proteomics Episode 7
The latest episode of 'Translating Proteomics' discusses the significance of proteoforms in biological research. Hosts Drs. Parag Mallick and Andreas Huhmer emphasize the need for routine measurement of proteoforms to enhance drug development and biomarker discovery. They highlight the dynamic nature of proteins and the technological advancements required for better proteoform analysis.
Read more →NAUT▲ +6%on this news
A vision for a more reproducible and robust future in the life sciences
At the US HUPO 2024, Nautilus Co-Founder Parag Mallick received the 2024 Gilbert S. Omenn Computational Proteomics Award. In his lecture, he discussed the importance of sharing not only data but also analysis infrastructures to enhance reproducibility and robustness in life sciences research. His vision aims to leverage AI-supported workflows to accelerate scientific discoveries.
Read more →NAUTAnimation – Proteoform analysis on the Nautilus Proteome Analysis Platform
Nautilus Biotechnology's platform allows for the analysis of proteoforms, which are modified proteins that can have various functions and characteristics. The platform's single-molecule analysis capability is crucial for understanding the proteoform makeup of biological samples. This could significantly advance the development of biomarkers and therapeutic drugs.
Read more →NAUTBringing AI to the World of Biology – Translating Proteomics Episode 6
The latest episode of 'Translating Proteomics' focuses on the integration of AI in biomedicine. Hosts Dr. Parag Mallick and Dr. Andreas Huhmer discuss the early successes of AI in biological research, its potential applications, and the challenges faced in its implementation. They emphasize the importance of data standardization for maximizing AI's impact in proteomics.
Read more →NAUTAnimation – Unlocking the potential of proteomics to fuel neuroscience
The article discusses the importance of proteomics in neuroscience, highlighting the role of the Nautilus Proteome Analysis Platform. This technology aims to improve the understanding of neurological disorders by identifying proteoform changes and potential biomarkers. It emphasizes the significance of targeting proteins abundant in diseased tissues for drug development.
Read more →NAUTNautilus Biotechnology to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
Nautilus Biotechnology, Inc. will participate in the Goldman Sachs 45th Annual Global Healthcare Conference, scheduled for June 10, 2024. The company's management will take part in a fireside chat at 8:40 a.m. Eastern Time. This event allows Nautilus to present its innovative protein analysis platform to a wider audience and demonstrates its commitment to the field of proteomics. Interested parties can access the presentation via Nautilus' website.
Read more →NAUTWhy the Dogma around Biology’s Central Dogma Is Wrong – Translating Proteomics Episode 5
The latest episode of 'Translating Proteomics' challenges the traditional central dogma of biology, which states that information flows from DNA to RNA to proteins. Hosts Dr. Parag Mallick and Dr. Andreas Huhmer argue that this view oversimplifies biological processes and advocate for new models that incorporate regulatory mechanisms. The episode emphasizes the importance of adapting our understanding of biology in light of modern research.
Read more →NAUTWhat is the Human Proteome Project?
The Human Proteome Project aims to identify and characterize all proteins in the human body, building on the Human Genome Project's foundation. Currently, it has identified 18,397 proteins, with efforts ongoing to find the remaining 1,400. The project is crucial for advancing proteomics technologies and understanding the roles of proteins in health and disease.
Read more →NAUTSingle-protein Biomarkers Don’t Cut It – Translating Proteomics Episode 4
In the latest episode of 'Translating Proteomics,' hosts Drs. Parag Mallick and Andreas Huhmer discuss the limitations of single-protein biomarkers in biological research. They emphasize the need for multi-protein and multiomic approaches to enhance biomarker discovery. The episode highlights the challenges faced in identifying effective biomarkers and the importance of proteome-scale data.
Read more →NAUTTreasures in the depths of the low abundance proteome
The article discusses the significance of low abundance proteins in the human blood proteome and their potential roles in health and disease. It highlights the Nautilus TM Proteome Analysis Platform's capability to identify these proteins, which are often overlooked due to their scarcity. The piece emphasizes the need for comprehensive proteomics studies to unlock the therapeutic potential of these understudied proteins.
Read more →NAUTNautilus Biotechnology Reports First Quarter 2024 Financial Results SEATTLE, WA
Nautilus Biotechnology, Inc. reported its financial results for the first quarter of 2024, indicating continued development progress on its proteomics platform. The company's operating expenses rose to $21.6 million, primarily due to increased headcount. Despite facing a larger net loss of $18.7 million, Nautilus holds $247.7 million in cash equivalents and investments. CEO Sujal Patel expressed confidence in the team's ability to establish a new standard for proteomic analysis while acknowledging the challenges ahead. A conference call is scheduled to further discuss these developments.
Read more →NAUTThe Proteome is Dynamic — Why That Matters – Translating Proteomics Episode 3
The latest episode of 'Translating Proteomics' discusses the dynamic nature of biological systems and the importance of incorporating spatial and temporal factors in experimental design. Hosts Drs. Parag Mallick and Andreas Huhmer highlight the need for proper data collection and sharing to understand complex biological interactions. The conversation aims to enhance scientific inquiry and innovation in proteomics.
Read more →NAUTWhat is digital proteomics?
Digital proteomics technologies provide discrete measurements of single protein molecules, contrasting with traditional analog methods that yield continuous data. The Nautilus Proteome Analysis Platform exemplifies this approach by isolating proteins and using machine learning for identification. This innovation enhances precision and understanding of protein dynamics, potentially revolutionizing research in biology and healthcare.
Read more →NAUTNautilus Biotechnology to Announce First Quarter 2024 Financial Results on April 30, 2024
Nautilus Biotechnology, Inc. announced it will report its first quarter 2024 financial results before the market opens on April 30, 2024. The company will host a conference call on the same day at 5:30 a.m. Pacific Time to discuss the results along with business developments and future outlook. This is part of Nautilus's mission to advance the field of proteomics through its innovative platform technology.
Read more →NAUTApplications of Proteomics, From Future Food to Biomarker Research – Translating Proteomics Episode 2
The latest episode of 'Translating Proteomics' highlights the diverse applications of proteomics in areas such as precision medicine, biomarker discovery, and even food production. Hosted by Drs. Parag Mallick and Andreas Huhmer from Nautilus Biotechnology, the episode emphasizes the growing impact of proteomics on various scientific fields. Listeners are encouraged to explore the potential of proteomics in transforming biological research.
Read more →NAUTNew podcast and video series – Translating Proteomics
Nautilus Biotechnology has launched a new podcast and video series titled 'Translating Proteomics', focusing on the significance of proteomics in various fields such as drug development and biomarker discovery. Hosted by Drs. Parag Mallick and Andreas Huhmer, the series aims to engage audiences in important scientific discussions and explore the potential breakthroughs in proteomics. The first episode discusses the current state and future possibilities of proteomics research.
Read more →NAUT▲ +6.1%on this news
Webinar – Expanding Proteomic Horizons with Single-Molecule Proteome and Proteoform Analysis
Nautilus is hosting a webinar to showcase its Proteome Analysis Platform, which focuses on single-molecule protein analysis. This technology aims to enhance proteomics through improved sensitivity and reproducibility, allowing for the identification of a vast majority of the human proteome. The webinar will detail recent advancements, including the quantification of complex proteoforms like tau, highlighting the platform's potential impact on biological research.
Read more →NAUTThe future of proteomics through the lens of US HUPO 2024
The US HUPO 2024 conference highlighted significant advancements in proteomics, emphasizing the importance of proteoforms in biological research. Nautilus showcased its next-generation proteomics platform, demonstrating its potential for identifying multi-protein biomarkers and enhancing precision medicine. The collaborative spirit among researchers aims to improve data accessibility and analysis techniques, paving the way for future discoveries.
Read more →NAUT▼ -19.1%on this news
Animation – Incredible dynamic range of the Nautilus Proteome Analysis Platform
Nautilus has introduced its Proteome Analysis Platform, designed to provide deep biological insights by matching the dynamic range of the proteome. This platform addresses the vast differences in protein abundances, enabling the detection of both low and high abundance proteins, which are crucial for understanding biological processes. The innovative approach includes advanced protein preparation techniques and single-molecule protein arrays.
Read more →NAUTWhat is quantitative proteomics?
Quantitative proteomics focuses on measuring protein abundance in biological samples, offering insights into protein activity and function. It surpasses qualitative methods by providing actionable data that can reveal molecular differences. Techniques vary from relative to absolute quantitation, with advancements like the Nautilus Platform enabling precise single-molecule measurements.
Read more →NAUTNautilus Biotechnology Reports Fourth Quarter and Fiscal Year 2023 Financial Results SEATTLE, WA
Nautilus Biotechnology reported its fourth quarter and fiscal year 2023 financial results, highlighting significant progress on its single molecule proteome analysis platform. The company experienced an increase in operating expenses and a higher net loss compared to the previous year. Despite these financial challenges, Nautilus maintains a robust cash position projected to sustain operations through 2026 and aims to launch its platform in 2025. CEO Sujal Patel emphasized the importance of the company's advancements in the proteomics field.
Read more →NAUTUsing proteomics to expand the scope of cancer research beyond driver mutations
The article discusses the advantages of proteomics over genomics in cancer research. It emphasizes that while driver mutations are important, they do not capture the full complexity of cancer biology. Proteomic analysis reveals critical information about protein abundance and activity, which can lead to better therapeutic targets and improved patient outcomes.
Read more →NAUTAdvantages of the Nautilus Proteome Analysis Platform – Rapid run time
The Nautilus Proteome Analysis Platform is designed to expedite proteomic analyses by significantly reducing run times. With its capability to analyze up to 10 billion proteins simultaneously using multi-affinity probes, the platform aims to provide comprehensive proteome coverage efficiently. This advancement is expected to facilitate faster insights in various research fields, including cancer and neuroscience.
Read more →NAUTFebruary 2024 round-up of podcasts and interviews featuring the Nautilus Founders
The article provides a roundup of recent podcasts and interviews featuring Nautilus Founders Sujal Patel and Parag Mallick. It highlights discussions on the importance of next-generation proteomics and the Nautilus Proteome Analysis Platform. The founders share their insights on proteoforms, aging, and the challenges of bringing innovative technologies to market.
Read more →NAUTBenefits of Iterative Mapping – Reproducibility
Nautilus has introduced the Iterative Mapping method within its Proteome Analysis Platform, focusing on reproducibility and robustness in proteomics research. This method enhances protein identification through multiple binding events and aims to simplify workflows for researchers. The platform addresses common frustrations with traditional proteomic analyses, promising reliable data and streamlined processes.
Read more →NAUTNautilus Biotechnology to Announce Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024
Nautilus Biotechnology, Inc. announced that it will report its financial results for the fourth quarter and full year of 2023 on February 28, 2024. The announcement includes plans for a conference call to discuss these results and provide insights into the company's business developments and outlook. This event emphasizes Nautilus's ongoing commitment to transforming proteomics and advancing human health.
Read more →NAUTApplications of proteomics – Food science
The article discusses the applications of proteomics in food science, highlighting its role in identifying allergenic proteins and discovering medicinal proteins in honey. It emphasizes the advancements in high-throughput proteomics techniques that improve food safety and nutrition. The potential of next-generation proteomics technologies is also noted, which may lead to safer and healthier food options.
Read more →NAUT▼ -6.4%on this news
Advantages of the Nautilus Proteome Analysis Platform – Accessibility
Nautilus has introduced its Proteome Analysis Platform, designed to make proteomics accessible to all researchers. The platform eliminates the need for complex sample pre-processing and offers easy digital protein quantification. Additionally, it includes software for data visualization, facilitating quicker insights into biological data. This initiative aims to broaden research participation and drive discoveries in various fields.
Read more →NAUTApplications of proteomics in cancer – Round up
The article discusses the significant role of proteomics in cancer research, emphasizing its ability to provide insights that genomics alone cannot. It highlights various studies demonstrating how multiomics approaches can identify new biomarkers, drug targets, and improve understanding of cancer subtypes. The advancements in proteomics tools are expected to accelerate the development of precision medicine.
Read more →NAUTCreating hyper-dense protein arrays for single-molecule proteomics
Nautilus has developed a new Proteomic Analysis Platform utilizing hyper-dense protein arrays designed to isolate single protein molecules. This advancement allows for the analysis of the entire proteome at once, significantly improving the efficiency and accessibility of single-molecule proteomics. The technology aims to facilitate comprehensive proteomic studies by enabling researchers to quantify a wide range of proteins.
Read more →NAUTAdvantages of the Nautilus Proteome Analysis Platform – Sensitivity
The Nautilus Proteome Analysis Platform addresses the sensitivity limitations of traditional proteomics by enabling single-molecule detection. This innovation allows for the identification and quantification of both rare and abundant proteins, enhancing researchers' ability to study complex biological processes. Key features include digital counting of proteins and the use of multi-affinity probes to improve accuracy.
Read more →NAUTInterview with Maureen Newman, Nautilus Senior Scientist, Bioanalytical Chemistry
Maureen Newman, a Senior Scientist at Nautilus, shares her journey in science and her current work in bioanalytical chemistry. She emphasizes the importance of understanding the proteome at a single-molecule level and its potential applications in diagnostics and therapy development. Newman appreciates the collaborative and supportive work culture at Nautilus, which fosters professional growth.
Read more →NAUTPodcast: Nautilus Founder and Chief Scientist Parag Mallick on “The Proteomics Show”
Parag Mallick, Founder and Chief Scientist of Nautilus, was featured on The Proteomics Show podcast. He discussed his efforts to enhance the accessibility of proteomics through ProteoWizard and highlighted Nautilus's innovative single-molecule proteomics platform. Mallick also shared insights from his career and expressed optimism about the future of proteomics.
Read more →NAUTAdvantages of the Nautilus Proteome Analysis Platform – Wide dynamic range
The Nautilus Proteome Analysis Platform is designed to analyze up to 10 billion single protein molecules in a single run, providing an unprecedented dynamic range for proteomic analysis. It utilizes massive arrays with 10 billion landing pads and DNA scaffolds to ensure efficient protein loading. This innovative approach aims to enhance the understanding of cellular functions and advance clinical development.
Read more →NAUTAnimation – Quantifying proteins on the Nautilus Proteome Analysis Platform
The Nautilus Proteome Analysis Platform enables precise protein quantification at the single-molecule level using a unique array of landing pads. This innovative technology employs multi-affinity probes to provide detailed insights into the proteome. Researchers are invited to join the Iterative Mapping Early Access Program to explore the platform's capabilities.
Read more →NAUTProtein “Guess Who I Am” – How the Nautilus Platform is designed to quantify billions of proteins at the single-molecule level
Nautilus has developed a groundbreaking platform designed to quantify billions of proteins at the single-molecule level. By employing a strategy akin to the game 'Guess Who I Am,' the platform uses non-specific multi-affinity probes to efficiently identify and quantify proteins across the entire proteome. This innovative approach significantly reduces the time and resources required for proteomic analysis compared to traditional methods.
Read more →NAUTApplications of proteomics in immunology – Outcomes of ubiquitylation in activated CD4+ T cells
The article discusses a study by Dybas et al. that utilized a multiomics approach to explore the role of ubiquitylation in activated CD4+ T cells. It highlights how ubiquitylation affects protein function and immune responses, revealing both degradative and non-degradative outcomes. The study emphasizes the potential of the Nautilus Proteome Analysis Platform in advancing proteomics research.
Read more →NAUT▼ -5.8%on this news
2023 Highlights from the Nautilus blog
In 2023, the Nautilus blog experienced substantial growth, increasing its monthly views significantly. The blog features key posts on the proteome, next-generation proteomics technologies, and their applications in drug development. Highlighted articles aim to educate readers on the importance of proteomics in advancing healthcare and research. The blog encourages subscriptions for ongoing updates.
Read more →NAUT▼ -5.3%on this newsshared move
Interview with Sonal Tonapi – Nautilus Manager, Probe Qualification
Sonal Tonapi, Manager at Nautilus, discusses her journey and motivations in the field of biology, driven by personal experiences with diseases. She highlights the growth of Nautilus and its innovative approach to proteomics, expressing excitement about the future of the company and its potential impact on healthcare. Tonapi emphasizes the importance of a supportive team environment in fostering creativity and problem-solving.
Read more →NAUTInterview with Martin Huber – VP of Biochemistry and Flow Cell Development
Martin Huber has joined Nautilus as VP of Biochemistry and Flow Cell Development, bringing a wealth of experience in genomics and proteomics. He emphasizes the transformative potential of the Nautilus Platform in analyzing proteins at a massive scale, which could significantly impact healthcare. Huber's vision includes democratizing proteomics and advancing biological research.
Read more →NAUTCongratulations to Nautilus Founder and Chief Scientist, Parag Mallick, winner of the 2024 US HUPO Gilbert S. Omenn Computational Proteomics Award
Parag Mallick, Chief Scientist at Nautilus, has been awarded the 2024 US HUPO Gilbert S. Omenn Computational Proteomics Award for his significant contributions to the field. His work, particularly in developing ProteoWizard, has improved mass spectrometry data analysis and accessibility. Nautilus continues to focus on making proteomics research more accessible and efficient.
Read more →NAUTApplications of proteomics in cancer – Multiomic study highlights the value of the proteome for prostate cancer prognoses
A recent study highlights the importance of proteomics in understanding prostate cancer. By applying multiomic analysis, researchers found that genetic changes often do not correlate with proteomic changes, revealing new insights into patient outcomes. The study emphasizes the potential of next-generation proteomics technologies to improve cancer diagnostics and treatment strategies.
Read more →NAUTNautilus Biotechnology Co-founder and Chief Scientist Parag Mallick, Ph.D., Honored with US HUPO Computational Proteomics Award
Nautilus Biotechnology announced that co-founder and Chief Scientist Parag Mallick, Ph.D., has been honored with the 2024 Gilbert S. Omenn Computational Proteomics Award by the US Human Proteome Organization. This award acknowledges his substantial contributions to bioinformatics and computational methods utilized in the proteomics community. Dr. Mallick will accept the award and present a lecture at the upcoming US HUPO conference in Portland, Oregon, scheduled for March 2024. The recognition highlights Nautilus' commitment to advancing the field of proteomics.
Read more →NAUTApplications of proteomics in cancer – assessing the potential of PROTACs
Researchers are advancing cancer treatment through PROTACs, which selectively degrade proteins in cancer cells while sparing healthy cells. A recent study demonstrated a PROTAC that effectively targets leukemia cells with minimal effects on platelets. This highlights the importance of proteomics in developing targeted therapies and understanding drug mechanisms in complex cellular environments.
Read more →NAUTApplications of proteomics in cancer – Proteomics reveals inner workings of head and neck squamous cell carcinoma (HNSCC)
The article discusses the role of proteomics in understanding head and neck squamous cell carcinoma (HNSCC), particularly its HPV-negative subtype. A multiomic analysis revealed significant insights into protein expression and potential biomarkers for treatment. The findings suggest that integrating proteomics with genomics can enhance precision medicine approaches for HNSCC. Next-generation proteomics tools are expected to facilitate broader research applications.
Read more →NAUT▼ -6.5%on this newsshared move
Applications of proteomics in neuroscience – Round up
The article discusses the growing applications of proteomics in neuroscience, particularly in understanding neurodegenerative diseases like Alzheimer's. It highlights several research studies that utilize advanced proteomics techniques to identify protein biomarkers and elucidate the mechanisms behind these diseases. The potential of next-generation proteomics technologies is also emphasized, suggesting a promising future for research in this field.
Read more →NAUTMapping the Alzheimer’s proteome – Applications of proteomics in neuroscience
A recent systematic review by Askenazi et al. analyzed 38 proteomic studies on Alzheimer's disease, revealing 54 proteins that are consistently altered across various stages and brain regions. This comprehensive approach highlights the importance of localized studies and identifies potential drug targets for early intervention. The use of next-generation proteomics platforms, like the Nautilus Proteome Analysis Platform, is emphasized for advancing Alzheimer's research.
Read more →NAUTInterview with Andreas Huhmer – Senior Director of Scientific Affairs and Alliance Management
Andreas Huhmer, recently appointed Senior Director at Nautilus, discusses the transformative potential of the Nautilus Proteome Analysis Platform. He highlights its accessibility and ability to simplify proteomic studies, moving beyond traditional mass spectrometry limitations. The platform is expected to facilitate comprehensive analysis of protein dynamics, which could revolutionize biomarker discovery and biological research.
Read more →NAUTApplications of proteomics in cancer – Insights from a multiomic analysis of lung adenocarcinoma
A recent multiomic analysis of lung adenocarcinoma samples has revealed critical insights into the disease's molecular underpinnings. The study identified various subtypes of adenocarcinoma, potential drug targets, and biomarkers linked to specific mutations. The findings underscore the importance of proteomics in advancing cancer diagnostics and treatment strategies.
Read more →NAUTNautilus eBook – Proteomics and cancer
The article discusses the role of proteomics in understanding cancer biology and developing precision medicine. It highlights recent findings from the Clinical Proteomic Tumor Analysis Consortium, emphasizing the potential of proteomics to identify cancer vulnerabilities. The eBook aims to showcase how these insights can lead to innovative diagnostics and therapeutics for cancer patients.
Read more →NAUTNautilus Biotechnology Appoints Martin Huber, Ph.D., as Vice President of Biochemistry and Flow Cell Development
Nautilus Biotechnology has appointed Martin Huber, Ph.D., as Vice President of Biochemistry and Flow Cell Development, expanding its R&D leadership team. Dr. Huber has over 20 years of experience in biotechnology startups and was previously the CEO of Quantapore. His expertise is expected to enhance Nautilus's capabilities as they prepare to launch their innovative single-molecule protein analysis platform next year. This strategic appointment aims to broaden the skillset within the company ahead of significant product developments.
Read more →NAUTHow targeted proteomics and targeted protein analyses are changing biology
The article discusses the advancements in targeted proteomics and targeted protein analyses, particularly through the Nautilus Proteome Analysis Platform. This technology allows for detailed examination of specific proteoforms, which can reveal significant biological insights and impact drug development. By enabling single-molecule analysis, researchers can better understand protein modifications and their implications in various biological contexts.
Read more →NAUT▲ +9.4%on this news· ran to +23% by day 3shared move
Nautilus Biotechnology Reports Third Quarter 2023 Financial Results SEATTLE, WA
Nautilus Biotechnology, Inc. reported its financial results for the third quarter of 2023, showing a net loss of $15.9 million compared to $14.1 million the previous year. The company is focused on preparing its single molecule proteome analysis platform for commercial launch next year and has noted a significant increase in operating expenses. Despite the losses, CEO Sujal Patel conveyed optimism regarding Nautilus's position in the growing proteomics sector, emphasizing ongoing commitments to financial discipline and product development.
Read more →NAUT▲ +11.4%on this news
Applications of proteomics in cancer – Identifying drivers and therapeutic opportunities in colon cancer
Recent research highlights the applications of proteomics in understanding colon cancer. A study by Vasaikar et al. identified distinct genomic and proteomic profiles among colon cancer subtypes, revealing potential therapeutic targets. The findings suggest that next-generation proteomics technologies could accelerate the development of targeted therapies and cancer vaccines.
Read more →NAUTApplications of proteomics in cancer – Proteomic analyses can reveal new breast cancer subtypes
A recent proteomic analysis of breast cancer samples has identified new subtypes, enhancing understanding of the disease. Conducted by researchers at the University of British Columbia, the study analyzed 300 specimens and found correlations between proteome-defined subtypes and treatment outcomes. This research highlights the potential for improved diagnostics and targeted therapies in breast cancer.
Read more →NAUTApplications of proteomics in cancer – Revealing molecular mechanisms of the epithelial to mesenchymal transition
The article discusses the role of proteomics in understanding the epithelial to mesenchymal transition (EMT) in cancer. It highlights a study by Paul et al. that utilized multiomic analyses to uncover distinct molecular pathways active at various stages of EMT. The findings suggest potential therapeutic targets for inhibiting EMT, which could improve cancer treatment.
Read more →NAUTInterview with Aimee Sanford – Nautilus Research Scientist
Aimee Sanford, a Research Scientist at Nautilus, shares her journey influenced by personal health challenges and her desire to make a positive impact in healthcare. Her supportive work environment and the innovative mission of Nautilus motivate her daily. Aimee emphasizes the importance of mentorship and collaboration in her role, highlighting the potential for significant advancements in healthcare.
Read more →NAUTNautilus Biotechnology to Announce Third Quarter Financial Results on October 31, 2023
Nautilus Biotechnology, Inc. has announced that it will report its third-quarter financial results on October 31, 2023, before the market opens. Alongside the results, the company will host a conference call to discuss its business developments and future outlook. The call is scheduled for 5:30 a.m. Pacific Time and will be accessible via the company's website, showcasing its commitment to investor engagement.
Read more →NAUTApplications of proteomics in cancer – Identifying potential biomarkers and therapeutic targets in pancreatic ductal adenocarcinoma
The article discusses the advancements in proteomics for identifying biomarkers and therapeutic targets in pancreatic ductal adenocarcinoma (PDAC). A multiomics approach has revealed critical insights into the disease's biology, linking genomic mutations to functional impacts and potential therapeutic interventions. The Nautilus TM Proteome Analysis Platform aims to enhance these discoveries, potentially improving early detection and treatment options for PDAC.
Read more →NAUTPaleoproteomics – Unleashing the proteome of the ancient world
Paleoproteomics studies ancient proteins, providing insights into extinct species and ancient cultures. Advanced techniques like mass spectrometry are crucial for analyzing these proteins, revealing information about ancient diets and trade routes. Despite challenges in identifying low-abundance proteins, the field is poised for significant discoveries as new technologies emerge.
Read more →NAUTAnimation – Unlocking the potential of proteomics to fuel precision medicine
Nautilus Biotechnology emphasizes the importance of proteomics in enhancing precision medicine. The Nautilus Proteome Analysis Platform aims to provide comprehensive proteomic analysis, which could lead to better drug targets and therapies. Traditional proteomics methods have limitations, but this new platform seeks to overcome these challenges by improving sensitivity and usability.
Read more →NAUTExpanding proteomic horizons at the HUPO 2023 World Congress
The HUPO 2023 World Congress showcased advancements in the Nautilus Proteome Analysis Platform, emphasizing its capability for single-molecule analysis of proteins. Key discussions highlighted the need for standardized workflows in proteomics and the platform's potential to enhance data reproducibility. Researchers expressed enthusiasm for using the platform to explore new avenues in proteomics, particularly in clinical applications.
Read more →NAUTThe understudied proteins initiative – A new opportunity for functional proteomics
The Understudied Proteins Initiative aims to address the significant gap in protein research, where 95% of studies focus on just 5,000 proteins. By leveraging emerging technologies, researchers hope to explore millions of understudied proteins, potentially unlocking new insights into biology, drug development, and disease biomarkers. The Nautilus Proteome Analysis Platform is a key tool in this effort.
Read more →NAUTUncovering protein networks in Alzheimer’s – Applications of proteomics in neuroscience
Recent research highlights the role of proteomics in understanding Alzheimer's disease. By linking the proteome to the genome, scientists are uncovering protein networks associated with the disease. This multiomics approach has revealed significant findings, including the identification of protein modules that correlate with Alzheimer's symptoms. The development of next-generation proteomics tools promises to enhance research and potentially lead to new treatments.
Read more →NAUTThe incredible power of proteins: The klotho protein enhances cognition in aged monkeys
Recent research published in Nature Aging reveals that the klotho protein can significantly enhance cognition in aged rhesus macaques. This study builds on previous findings in mice, suggesting klotho's potential as a neuroprotective agent. As klotho levels decrease with age in humans, these findings could lead to therapeutic applications for cognitive decline associated with aging.
Read more →NAUT▼ -6.8%on this newsshared move
Linking genes and proteins in neurological disease – Applications of proteomics in neuroscience
Recent advancements in proteomics are enhancing our understanding of neurological diseases such as Alzheimer's and Parkinson's. Researchers are utilizing next-generation proteomics technologies to analyze proteins across various tissue samples, revealing intricate links between genes and protein expression. This research could pave the way for new biomarkers and therapeutic targets in treating these complex conditions.
Read more →NAUTProximity proteomics for the identification of axonal proteomes – Applications of proteomics in neuroscience
The article discusses the application of proximity proteomics in neuroscience, focusing on the identification of axonal proteomes. Researchers utilized a mouse model to isolate axon-enriched proteins, revealing associations with neurological disease risk genes. The findings highlight the potential of next-generation proteomics technologies, such as the Nautilus Platform, to advance understanding of brain functions and related disorders.
Read more →NAUTWhat is single-molecule analysis?
Single-molecule analysis focuses on studying proteins at the individual molecule level, offering unprecedented resolution in proteomic research. The Nautilus Platform is at the forefront of this technology, enabling the identification and quantification of proteins and their variants, known as proteoforms. This advancement could significantly impact drug development and disease diagnostics, particularly in identifying biomarkers for early detection of conditions like cancer.
Read more →NAUTIdentifying disrupted pathways in dementia – Applications of proteomics in neuroscience
The article discusses the application of proteomics in identifying disrupted biological pathways in neurodegenerative diseases, particularly dementia. It highlights a study that utilized a multiomics approach to uncover potential biomarkers and therapeutic targets. The findings suggest that specific protein modules are associated with disease progression, emphasizing the importance of proteomics in neuroscience research.
Read more →NAUTWhat is functional proteomics?
Functional proteomics focuses on understanding the roles of proteins in cellular processes. It employs various techniques, including protein co-expression and protein-protein interaction analyses, to uncover how proteins function and interact. The Nautilus Proteome Analysis Platform represents a significant advancement in this field, enabling researchers to access a vast array of proteins for study. This approach has proven instrumental in identifying viral proteins during the COVID-19 pandemic, leading to potential treatment discoveries.
Read more →NAUT▲ +5.8%on this newsshared move
Assessing tau modifications during Alzheimer’s disease progression – Applications of proteomics in neuroscience
Recent research highlights the role of tau protein modifications in Alzheimer's disease progression. Utilizing the FLEXITau technique, researchers identified various tau modifications and correlated them with disease severity. This work may pave the way for improved diagnostics and therapeutic strategies targeting specific tau proteoforms. Future studies aim to enhance understanding of tau's role in neurodegenerative diseases.
Read more →NAUTNautilus Biotechnology to Participate in Upcoming August Investor Conferences
Nautilus Biotechnology, Inc. (NASDAQ: NAUT) has announced its participation in several upcoming investor conferences, including the Canaccord 43rd Annual Growth Conference and the UBS MedTech, Tools and Genomics Summit 2023. Management is set to participate in a panel discussion on the future of proteomics and will hold one-on-one meetings with investors. This involvement underscores the company's commitment to advancing its innovative protein analysis platform and its efforts to engage with the investment community.
Read more →NAUTInteraction proteomics explores the role of tau in health and disease – Applications of proteomics in neuroscience
Recent research using interaction proteomics has uncovered the roles of tau protein in synaptic vesicle trafficking and cellular energetics, which may be disrupted in Alzheimer's disease. The study highlights the potential for developing biomarkers and treatments targeting these pathways. Additionally, advancements in next-generation proteomics aim to make such research more accessible.
Read more →NAUTNautilus Biotechnology Reports Second Quarter 2023 Financial Results SEATTLE, WA
Nautilus Biotechnology, Inc. reported its financial results for the second quarter of 2023, indicating solid progress towards launching its single molecule proteome analysis platform. The company's CEO highlighted the integration of platform elements essential for future market launch, expressing confidence in their financial management that supports operations through 2026. However, Nautilus also reported a 23% increase in operating expenses compared to the previous year, and a net loss of $15.8 million, which is higher than the previous year’s loss.
Read more →NAUTWhat proteomics can tell us about dreaming
The article explores the potential of proteomics to uncover the molecular mechanisms behind dreaming and REM sleep. It discusses the role of acetylcholine in REM sleep and how analyzing the human proteome can identify proteins linked to dreaming. The research may lead to insights into REM-related disorders and the benefits of understanding dreams for mental health.
Read more →NAUTApplications of proteomics in agriculture – Disease resistance
The article discusses the role of proteomics in enhancing disease resistance in crops. It highlights how proteomic analysis identifies proteins involved in plant defense against pathogens like fungi and viruses. Research findings indicate potential strategies for developing disease-resistant crops, which could significantly impact agricultural productivity and food security.
Read more →NAUTApplications of proteomics in agriculture – Plant stress tolerance
The article discusses the role of proteomics in enhancing plant stress tolerance amid climate change. It highlights research on proteins that help crops like maize and chickpeas withstand drought and salinity. The Nautilus Proteome Analysis Platform is noted for its potential to improve proteomic studies, aiding in the development of resilient crop varieties. Future articles will explore disease resistance in agriculture.
Read more →NAUT3 ways next-generation proteomics can impact neuroscience – Applications of proteomics in neuroscience
Next-generation proteomics is set to revolutionize neuroscience by providing comprehensive insights into the proteome. Technologies like the Nautilus Proteome Analysis Platform allow researchers to analyze proteins involved in neuronal development, signaling, and diseases such as Alzheimer's. This advancement could lead to novel biomarkers and treatments for neurological disorders.
Read more →NAUTUsing proteomics to personalize medicine across the continuum of care (Part 2)
The article discusses the potential of proteomics in advancing personalized medicine. It highlights how next-generation proteomics technologies can provide objective biological measures of disease, improving treatment efficacy and enabling early detection of health issues. The integration of proteomics with traditional genomics could enhance preventive care and ultimately lead to more effective personalized treatments.
Read more →NAUTNautilus Biotechnology to Announce Second Quarter Financial Results on August 2, 2023
Nautilus Biotechnology, Inc. has announced it will report its second-quarter financial results on August 2, 2023, before the market opens. The company plans to host a conference call at 5:30 a.m. PT to discuss these results alongside business developments and future outlook. Nautilus focuses on revolutionizing proteomics through its innovative protein analysis platform.
Read more →NAUTNautilus Biotechnology to Participate in Upcoming June Investor Conferences
Nautilus Biotechnology, Inc. announced its participation in two investor conferences in June 2023. The company will host a fireside chat at the Jefferies 2023 Healthcare Conference on June 8th and another at the Goldman Sachs 44th Annual Global Healthcare Conference on June 12th. These presentations aim to highlight Nautilus' advancements in single-molecule protein analysis and the potential impact on human health. Interested participants can access the webcasts through the company's website.
Read more →NAUT▼ -10.6%on this news
Nautilus Biotechnology Reports First Quarter 2023 Financial Results SEATTLE, WA
Nautilus Biotechnology reported its financial results for the first quarter of 2023, showing a net loss of $15.0 million, down from $15.8 million in the same period last year. The company achieved significant milestones, including the granting of 4 new U.S. patents and the announcement of winners in its First Access Challenge, which engages researchers in various scientific areas. The increase in operating expenses, however, raises concerns about the company’s financial management as it progresses towards its platform launch planned for mid-2024.
Read more →NAUT▼ -6.4%on this news
Nautilus Biotechnology to Announce First Quarter Financial Results on May 2, 2023
Nautilus Biotechnology, Inc. has announced that it will report its first quarter financial results on May 2, 2023. A corresponding conference call will be held to discuss the results and business developments. This reflects the company's commitment to transparency and ongoing engagement with its investors. Nautilus is focused on advancing protein analysis technology and its role in proteomics.
Read more →NAUTNautilus Biotechnology to Participate in B. Riley Securities’ Disruptive Biotech Enabling Technologies – Proteomics, Virtual Conference
Nautilus Biotechnology, Inc. has announced its participation in the B. Riley Securities' Disruptive Biotech Enabling Technologies – Proteomics Virtual Conference. The company will host a fireside chat on April 6th to discuss its innovations in protein analysis. Nautilus aims to transform proteomics and advance human health through its platform technology. The event is expected to enhance engagement with investors and stakeholders in the biotechnology space.
Read more →NAUTNautilus Biotechnology Announces “First Access Challenge” Winners
Nautilus Biotechnology has announced the winners of its First Access Challenge, selecting three research proposals aimed at advancing proteomic analysis. The winning projects, announced at the US HUPO 2023 Conference, cover areas such as therapeutics for acute kidney injuries, the pathology of pulmonary fibrosis, and cancer therapies for glioma. The winners will gain early access to Nautilus' single-molecule proteomic data and work collaboratively with Nautilus scientists. This initiative is expected to spur significant developments in biomedical research.
Read more →NAUT▼ -7%on this news
Nautilus Biotechnology Reports Fourth Quarter and Fiscal Year 2022 Financial Results SEATTLE, WA
Nautilus Biotechnology reported its fourth quarter and fiscal year 2022 financial results, revealing a strategic partnership with TGen to study protein targets in DIPG. Despite increasing operating expenses to support product development and a net loss of $57.9 million for the year, the company reported decreased spending from the previous quarter and substantial cash reserves. Nautilus also presented significant scientific findings at industry conferences and expanded its footprint by opening a new office in San Diego. The CEO expressed optimism about future developments and the upcoming commercial launch.
Read more →NAUT▼ -10.3%on this newsshared move
Nautilus Biotechnology to Participate in the 43rd Annual Cowen Health Care Conference
Nautilus Biotechnology, Inc. announced its participation in the 43rd Annual Cowen Health Care Conference, scheduled for March 6th. The event will include a fireside chat featuring management, which can be accessed through a live webcast on the company's website. Nautilus is recognized for its pioneering work in single-molecule protein analysis, aiming to advance the field of proteomics. The event presents an opportunity for stakeholders to gain insights into the company's developments and mission.
Read more →NAUTNautilus Biotechnology to Announce Fourth Quarter and Full Year 2022 Financial Results on February 23, 2023
Nautilus Biotechnology, Inc. is set to announce its financial results for the fourth quarter and full year of 2022 on February 23, 2023. The announcement will include a conference call at 5:30 a.m. Pacific Time, where management will discuss the results and the company's outlook. Nautilus is focused on developing a platform technology for protein analysis, aimed at advancing the field of proteomics.
Read more →NAUTNautilus Biotechnology Expands to San Diego
Nautilus Biotechnology has announced the opening of a new office in San Diego, California, as part of its expansion strategy. The 7,000-square-foot facility will accommodate various departments, including engineering and bioinformatics, enhancing the company's capacity for research and development. This move is intended to leverage San Diego's biotech community and further Nautilus's mission to advance the understanding of the human proteome. The company is also involved in collaborations with notable organizations such as TGen and Genentech.
Read more →NAUTNautilus Biotechnology Partners with the Translational Genomics Research Institute (TGen) to Investigate Applications of Single-Molecule Proteomic Analysis in Diffuse Intrinsic Pontine Glioma (DIPG)
Nautilus Biotechnology has announced a partnership with the Translational Genomics Research Institute (TGen) to explore the applications of its single-molecule proteomics platform in the study of diffuse intrinsic pontine glioma (DIPG), a rare childhood brain cancer. The collaboration aims to understand the epigenetic mechanisms of DIPG by investigating specific protein targets at the single-molecule level. While this partnership represents a step forward for Nautilus, their product platform remains in development and faces various challenges before commercialization. The team plans to publish findings once the study concludes.
Read more →NAUT▼ -6.5%on this news
Nautilus Biotechnology Launches “First Access Challenge”
SEATTLE, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced the launch of the First Access Challenge, a research competition f
Read more →NAUTNautilus Biotechnology Reports Third Quarter 2022 Financial Results SEATTLE, WA
Nautilus Biotechnology Reports Third Quarter 2022 Financial Results SEATTLE, WA, November 1, 2022 - Nautilus Biotechnology, Inc. (NASDAQ NAUT or "Nautilus"), a company pioneering a single molecule proteome analysis platform, today reported financial results for the third quarter
Read more →NAUT▼ -7.3%on this news
Nautilus Biotechnology to Announce Third Quarter 2022 Financial Results on November 1, 2022
SEATTLE, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced it will report financial results for the third quarter 2022 before
Read more →NAUTNautilus Biotechnology to Participate in the Capital One Spatial Biology & Proteomics Summit
SEATTLE, Sept. 23, 2022 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced the company will be participating in the upcoming Capital One Spa
Read more →NAUTNautilus Biotechnology Joins Human Proteome Organization (HUPO) Industrial Advisory Board
SEATTLE, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced it has joined the Human Proteome Organization (HUPO) Industrial A
Read more →NAUTNautilus Biotechnology to Participate in the Morgan Stanley Global Healthcare Conference
SEATTLE, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced the company will be participating in the upcoming Morgan Stanley G
Read more →NAUTNautilus Biotechnology Reports Second Quarter 2022 Financial Results SEATTLE, WA
Nautilus Biotechnology Reports Second Quarter 2022 Financial Results SEATTLE, WA, August 2, 2022 - Nautilus Biotechnology, Inc. (NASDAQ NAUT or "Nautilus"), a company pioneering a single molecule proteome analysis, today reported financial results for the second quarter ended Ju
Read more →NAUTNautilus Biotechnology Appoints Eric Spence as Vice President of Instrument Engineering and Ken Kuhn, Ph.D., as Vice President of Reagent and Platform Development
SEATTLE, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced further expansion of its management team with the appointments of
Read more →NAUTNautilus Biotechnology to Announce Second Quarter 2022 Financial Results on August 2, 2022
SEATTLE, July 13, 2022 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced it will report financial results for the second quarter 2022 befor
Read more →NAUTNautilus Biotechnology Reports First Quarter 2022 Financial Results SEATTLE, WA
Nautilus Biotechnology Reports First Quarter 2022 Financial Results SEATTLE, WA, May 3, 2022 - Nautilus Biotechnology, Inc. (NASDAQ NAUT or "Nautilus"), a company pioneering a single molecule proteome analysis, today reported financial results for the first quarter ended March 3
Read more →NAUTNautilus Biotechnology Appoints Gwen Weld as Chief People Officer and Sheri Wilcox, Ph.D., as Vice President of Affinity Reagent Development
SEATTLE, April 12, 2022 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced the appointments of Gwen Weld as Chief People Officer and Sheri W
Read more →NAUTNautilus Biotechnology to Announce First Quarter 2022 Financial Results on May 3, 2022
SEATTLE, April 07, 2022 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced it will report financial results for the first quarter 2022 befor
Read more →NAUTNautilus Biotechnology to Present at EuPA and AACR Meetings
• Co-founder and Chief Scientist Parag Mallick, Ph.D., to present lecture at Annual Congress of the European Proteomics Association (EuPA) • Associate Director Greg Kapp, Ph.D., to present poster at American Association for Cancer Research (AACR) Annual Meeting SEATTLE, April 0
Read more →NAUTNautilus Biotechnology Appoints Karen Akinsanya, Ph.D., to Board of Directors Schr dinger President of R D, Therapeutics brings extensive leadership in commercializing breakthrough biotechnologies to company developing p
Nautilus Biotechnology Appoints Karen Akinsanya, Ph.D., to Board of Directors Schr dinger President of R D, Therapeutics brings extensive leadership in commercializing breakthrough biotechnologies to company developing platform for comprehensively quantifying the proteome to ena
Read more →NAUT▲ +8.4%on this news
Nautilus Biotechnology Reports Fourth Quarter and Fiscal Year 2021 Financial Results SEATTLE, WA
Nautilus Biotechnology Reports Fourth Quarter and Fiscal Year 2021 Financial Results SEATTLE, WA, February 24, 2022 - Nautilus Biotechnology, Inc. (NASDAQ NAUT or "Nautilus"), a company pioneering a single molecule proteome analysis platform, today reported financial results for
Read more →NAUTNautilus to Participate in the 42nd Annual Cowen Health Care Conference
SEATTLE, Feb. 16, 2022 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced the company will be participating virtually in the upcoming 42nd A
Read more →NAUT▼ -6.7%on this news
Nautilus Biotechnology to Announce Fourth Quarter and Full Year 2021 Financial Results on February 24, 2022
SEATTLE, Jan. 27, 2022 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced it will report financial results for the fourth quarter and full y
Read more →NAUT▲ +7.2%on this news
Nautilus Biotechnology Reports Third Quarter 2021 Financial Results SEATTLE, WA
Nautilus Biotechnology Reports Third Quarter 2021 Financial Results SEATTLE, WA, November 2, 2021 - Nautilus Biotechnology, Inc. (NASDAQ NAUT or "Nautilus"), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today reported financial r
Read more →NAUT▲ +7.2%on this news
Nautilus and Abcam Announce Strategic Partnership to Accelerate Exploration of the Proteome
SEATTLE and CAMBRIDGE, United Kingdom, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, and Abcam (AIM:ABC; NASDAQ:ABCM), a global innovator
Read more →NAUTNautilus Biotechnology to Announce Third Quarter of Fiscal Year 2021 Financial Results on November 2, 2021
SEATTLE, Oct. 11, 2021 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced it will report financial results for the third quarter of fiscal y
Read more →NAUTNautilus to Participate in the Morgan Stanley Global Healthcare Conference
SEATTLE, Sept. 03, 2021 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the human proteome, today announced the company will be participating virtually in the upcoming
Read more →NAUT▼ -5%on this news
Nautilus Biotechnology Reports Second Quarter 2021 Financial Results
SEATTLE, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a life sciences company creating a platform technology for quantifying and unlocking the complexity of the proteome, today reported financial results for the second quarter ende
Read more →NAUT▲ +6.7%on this newsshared move
Nautilus Biotechnology Appoints Karl Voss, Ph.D., as Vice President of Life Sciences Research and Development
SEATTLE, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced the appointment of Karl Voss, Ph.D., as Vice President of Life Sci
Read more →NAUTNautilus Biotechnology to Announce Second Quarter of Fiscal Year 2021 Financial Results on August 10, 2021
SEATTLE, July 13, 2021 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced it will report financial results for the second quarter of fiscal
Read more →NAUTNautilus Biotechnology Appoints Emma Lundberg, Ph.D., to Scientific Advisory Board
SEATTLE, June 17, 2021 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced the appointment of Emma Lundberg, Ph.D. to its Scientific Advisory
Read more →NAUTFinancial Information Nautilus Biotechnology, Inc. Unaudited Condensed Financial Statements As of
Financial Information Nautilus Biotechnology, Inc. Unaudited Condensed Financial Statements As of March 31, 2021 and December 31, 2020 and for the Three Months Ended March 31, 2021 and 2020 Page(s) Nautilus Biotechnology, Inc. Unaudited Condensed Financial Statements Conden
Read more →NAUTNautilus Biotechnology Debuts as Publicly Traded Company, Seeks to Deliver on the Untapped Potential of the Human Proteome
Business combination transaction with Arya Sciences Acquisition Corp III, a special purpose acquisition company sponsored by Perceptive Advisors, closed on June 9, 2021 Publicly traded company renamed Nautilus Biotechnology, Inc. Common stock commences trading under ticker symb
Read more →NAUTARYA Sciences Acquisition Corp III Announces Extraordinary General Meeting Teleconference Details NEW YORK, NY, JUNE 1, 2021-ARYA Sciences Acquisition Corp III ("ARYA") (Nasdaq: ARYA), today announced that, due to the pu
ARYA Sciences Acquisition Corp III Announces Extraordinary General Meeting Teleconference Details NEW YORK, NY, JUNE 1, 2021-ARYA Sciences Acquisition Corp III ("ARYA") (Nasdaq: ARYA), today announced that, due to the public health and safety concerns related to the coronavirus
Read more →NAUTFiled by ARYA Sciences Acquisition Corp III Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: ARYA Sciences Acquisition
Filed by ARYA Sciences Acquisition Corp III Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: ARYA Sciences Acquisition Corp III Commission File No. 001-39434 Nautilus Biot
Read more →NAUTNext-Gen Proteomics Company Nautilus Biotechnology to List on Nasdaq Through Merger with Arya Sciences Acquisition Corp III Nautilus Biotechnology has entered into a definitive merger agreement with Arya Sciences Acquisi
Next-Gen Proteomics Company Nautilus Biotechnology to List on Nasdaq Through Merger with Arya Sciences Acquisition Corp III Nautilus Biotechnology has entered into a definitive merger agreement with Arya Sciences Acquisition Corp III (Nasdaq: ARYA). Upon closing, the combined
Read more →NAUTARYA SCIENCES ACQUISITION CORP III Report of Independent Registered Public Accounting Firm F-2 Balance Sheet F-3 Notes to Balance Sheet F-4 Report of Independent Registered Public Accounting Firm To the Shareholders and
ARYA SCIENCES ACQUISITION CORP III Report of Independent Registered Public Accounting Firm F-2 Balance Sheet F-3 Notes to Balance Sheet F-4 Report of Independent Registered Public Accounting Firm To the Shareholders and the Board of Directors of ARYA Sciences Acquisition Corp
Read more →Competitive Position
How NAUT ranks across every disease it competes inCompetitive Position is a premium feature
See how NAUT ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial